Abstract

IMPORTANT. Reported increases in attention-deficit/hyperactivity disorder (ADHD) diagnoses are accompanied by growing debate about the underlying factors. Although overdiagnosis is often suggested, no comprehensive evaluation of evidence for or against overdiagnosis has ever been undertaken and is urgently needed to enable evidence-based, patient-centered diagnosis and treatment of ADHD in contemporary health services.

OBJECTIVE. To systematically identify, appraise, and synthesize the evidence on overdiagnosis of ADHD in children and adolescents using a published 5-question framework for detecting overdiagnosis in noncancer conditions.

EVIDENCE REVIEW. This systematic scoping review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Extension for Scoping Reviews and Joanna Briggs Methodology, including the PRISMA-ScR Checklist. MEDLINE, Embase, PsychINFO, and the Cochrane Library databases were searched for studies published in English between January 1, 1979, and August 21, 2020. Studies of children and adolescents (aged ≤18 years) with ADHD that focused on overdiagnosis plus studies that could be mapped to 1 or more framework question were included. Two researchers independently reviewed all abstracts and full-text articles, and all included studies were assessed for quality.

FINDINGS. Of the 12,267 potentially relevant studies retrieved, 334 (2.7%) were included. Of the 334 studies, 61 (18.3%) were secondary and 273 (81.7%) were primary research articles. Substantial evidence of a reservoir of ADHD was found in 104 studies, providing a potential for diagnoses to increase (question 1). Evidence that actual ADHD diagnosis had increased was found in 45 studies (question 2). Twenty-five studies showed that these additional cases may be on the milder end of the ADHD spectrum (question 3), and 83 studies showed that pharmacological treatment of ADHD was increasing (question 4). A total of 151 studies reported on outcomes of diagnosis and pharmacological treatment (question 5). However, only 5 studies evaluated the critical issue of benefits and harms among the additional, milder cases. These studies supported a hypothesis of diminishing returns in which the harms may outweigh the benefits for youths with milder symptoms.

CONCLUSIONS AND RELEVANCE. This review found evidence of ADHD overdiagnosis and overtreatment in children and adolescents. Evidence gaps remain and future research is needed, in particular research on the long-term benefits and harms of diagnosing and treating ADHD in youths with milder symptoms; therefore, practitioners should be mindful of these knowledge gaps, especially when identifying these individuals and to ensure safe and equitable practice and policy.
Introduction

Public debate over the appropriateness of attention-deficit/hyperactivity disorder (ADHD) diagnosis has grown along with diagnosis rates.\(^1\)\(^-\)\(^6\) Disagreement continues about how much of the increased diagnoses can be attributed to true increases in frequency, improved detection, or diagnostic inflation because of misdiagnosis and/or overdiagnosis.\(^7\)\(^-\)\(^12\) The concept of overdiagnosis is well established in cancer,\(^13\)\(^,\)\(^14\) but it also occurs in noncancer conditions.\(^15\)\(^-\)\(^17\) Methods to investigate overdiagnosis in noncancer conditions were published recently\(^18\) but have not been applied to ADHD yet.

Overdiagnosis of ADHD could happen because of diagnostic inflation\(^10\)\(^,\)\(^19\) by widening the definition to include ambiguous or mild symptoms, by explicitly changing the diagnostic definition,\(^10\)\(^,\)\(^20\) or by implicitly medicalizing behavioral patterns that previously would not have been considered abnormal\(^21\) (eg, those behaviors that are typical of children who are relatively young for their school year\(^22\)). However, for increased detection to represent current overdiagnosis rather than previous underdiagnosis of ADHD, we also need evidence that these additional cases do not derive a net benefit from diagnosis (ie, these children’s overall health is not improved because the harms of diagnosis and treatment outweigh the benefits\(^23\)\(^-\)\(^25\)). Although the benefits of appropriate diagnosis and treatment of ADHD may be well known,\(^12\) harms are less well appreciated. Physical and psychosocial harms (and financial costs) may be experienced directly by the young patients and their family, but economic and opportunity costs are experienced by the wider society.\(^7\)

In this study, we systematically reviewed the literature to identify, appraise, and synthesize the evidence on overdiagnosis of ADHD in children and adolescents. Moreover, we aimed to highlight any existing evidence gaps. We used a 5-question framework for detecting overdiagnosis in noncancer conditions.

Methods

Because of the broad research question, we conducted a systematic scoping review that adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Extension for Scoping Reviews\(^26\) and Joanna Briggs Methodology,\(^27\) including the provision of a PRISMA-ScR Checklist. A summary of the methods is given here, and the details are published elsewhere.\(^28\)

Overdiagnosis is defined here as occurring when a person is clinically diagnosed with a condition, but the net effect of the diagnosis is unfavorable.\(^18\)\(^,\)\(^23\)\(^,\)\(^29\) Misdiagnosis (when a child is incorrectly labeled with an ADHD diagnosis instead of an alternative condition\(^10\)\(^,\)\(^23\)) and false-positive diagnosis (when a subsequent clinical encounter reveals a wrong initial diagnosis\(^23\)) are not the focus of this article.

The conceptual basis for this review was a previously published framework for identifying characteristics that are consistent with overdiagnosis and subsequent overtreatment in noncancer conditions.\(^18\) All included data were mapped to these 5 questions: (1) Is there potential for increased diagnosis? (2) Has diagnosis actually increased? (3) Are additional cases subclinical or low risk? (4) Have some additional cases been treated? (5) Might harms outweigh benefits of diagnosis (5a) and treatment (5b) (Figure 1)?

Peer-reviewed primary and secondary studies in children and adolescents that were published in English between January 1, 1979, and August 21, 2020, were eligible for inclusion. Studies with mixed-age populations were included if it was possible to extract data from them separately or if most participants were aged 18 years or younger. Given the overwhelming amount of evidence on pharmacological ADHD treatment outcomes, we included systematic reviews and cohort studies only for question 5b. Studies needed to have a clear emphasis on ADHD.

Searches were performed on August 21, 2020, in MEDLINE, Embase, PsychINFO, and the Cochrane Library (eAppendix 1 in Supplement 1). These database searches were supplemented by backward citation searches of all included articles and forward citation searches on key research.
After the removal of duplicates and a pilot phase, 2 of us (L.K. and R.S.) independently screened abstracts using the web-based text mining tool Abstrackr (Brown University). Subsequently, the full texts of all potential articles were independently reviewed by 1 of us (L.K.) and another researcher. Any discrepancies were resolved through discussion.

**Data Extraction and Quality Assessment**
Data were extracted into a standardized template, which was developed through an iterative process (eAppendix 2 in Supplement 1). Data from qualitative studies were mapped using NVivo, version 12 Plus (QSR International). Uncertainties were resolved by team discussion. A quality assessment of included studies was conducted by one of us (L.K.) using critical appraisal checklists developed by the Joanna Briggs Institute.

**Data Synthesis and Analysis**
Data were considered in the context of the 5 questions and then stratified into themes and subthemes for analysis. Each study could contribute data to more than 1 question.

To investigate whether a reservoir of potentially diagnosable ADHD existed (question 1), we looked for prevalence variations and other indicators, such as evidence of a spectrum of symptoms. For example, the lack of biological explanations for large prevalence variations among populations or among diagnostic standards would indicate a reservoir of potentially diagnosable disease. To analyze the data on ADHD diagnosis and treatment patterns (questions 2 and 4), we included any studies that provided time-trend data on clinical diagnosis or medication rates.

The question of whether additional diagnoses were predominantly mild cases (question 3) was central to ascertaining whether extra detection represented a net benefit or harm. However, severity of ADHD was not consistently defined or assessed, relying heavily on subjective interpretations. We grouped the evidence for this question into 2 categories: studies that reported ADHD severity and studies that reported degree of impairment as a proxy.

We divided the evidence on benefits and harms (question 5) into outcomes of the diagnosis and outcomes of any subsequent treatment, with a focus on the ratio of benefits to harms specifically for youths with milder ADHD-related behaviors. In addition, we considered the evidence on benefits and harms across the wider ADHD spectrum.

**Figure 1. Five-Question Framework for Identifying Potential Attention-Deficit/Hyperactivity Disorder (ADHD) Overdiagnosis**

The model of an iceberg illustrates how the framework relates to subsets of the population who may be diagnosed with ADHD. Question 1 concerns youths who may be diagnosable with ADHD, question 2 concerns youths who are diagnosed with ADHD according to newer criteria or those who were already diagnosed with ADHD using older thresholds, and questions 3 to 5 concern youths who are newly diagnosed vs those who are already diagnosed (adapted from Bell et al^29).
Results

Of the 12,267 records retrieved, 334 studies (2.7%) were included. eAppendix 3 in Supplement 1 outlines the selection process in a PRISMA flow diagram.26

Of the 334 included studies, 61 (18.3%) were secondary and 273 (81.7%) were primary research articles. Most studies were published within the past 10 years (n = 217 [65.0%]) and were most commonly from North America (n = 128 [38.3%]), Europe (n = 93 [27.8%]), or Oceania/Asia (n = 35 [10.5%]) (Table 1; eAppendix 4 in Supplement 1 and Supplement 2).

The quality of included studies varied; approximately one-third of the studies were classified as having low (n = 129), moderate (n = 102), or high (n = 103) risk of bias. Studies that provided evidence for question 5 were more likely to be at high risk of bias (n = 69 [45.7%]) (Figure 2 and eAppendix 5 in Supplement 1).

Table 2 maps the evidence against the framework.1,3,5,6,10,11,20-22,33-35 A summary of the findings is described here. The full results are provided in eAppendix 6 in Supplement 1.

Large Reservoir of Potentially Diagnosable ADHD

A total of 104 studies were included to answer question 1. Large variations in ADHD diagnosis were found between subpopulations in 48 studies. Twenty-five studies provided evidence of variation between the sexes, showing lower diagnosis of ADHD in girls than in boys. Although biological reasons may exist,38,45 equally symptomatic girls were less likely to be diagnosed than boys in 2 studies.54,55 Eight studies showed decreasing ratios over time, which were indicative of a reservoir of diagnosable ADHD in girls.5,6,34,37,40,41,44,47

Of the 12 included studies that focused on relative age, 11 studies showed that the youngest children in class were more likely to be diagnosed with ADHD than the oldest children.22,68-77 One study did not confirm this finding.78 It was conducted in a low-prevalence setting in which only

---

Table 1. General Characteristics of Included Sources of Evidence

| Characteristic           | No. (%) |
|--------------------------|---------|
| Total No.                | 334     |
| Year of publication      |         |
| 1979-1990                | 5 (1.5) |
| 1991-2000                | 23 (6.9)|
| 2001-2010                | 89 (26.6)|
| 2011-2020                | 217 (65.0)|
| Region                   |         |
| North America            | 128 (38.3)|
| Rest of Europe           | 35 (10.5)|
| Scandinavia              | 33 (9.9)|
| United Kingdom/Ireland   | 25 (7.5)|
| Asia                     | 18 (5.4)|
| Australia/New Zealand    | 17 (5.1)|
| Middle East              | 10 (3.0)|
| Not specified/various regions | 68 (20.4) |
| Study design             |         |
| Cohort                   | 90 (26.9)|
| Cross-sectional          | 6 (1.8)|
| Diagnostic test accuracy | 9 (2.7)|
| Prevalence               | 142 (42.5)|
| Qualitative              | 12 (3.6)|
| Randomized clinical trial| 14 (4.2)|
| Systematic review        | 44 (13.9)|
| Other review             | 17 (5.1)|
specialists diagnosed ADHD, suggesting that variation (and a potential reservoir) is much smaller where stricter adherence to diagnostic criteria may occur.

Youths from various migrant backgrounds were traditionally less likely to be diagnosed with ADHD in 15 studies. However, there is evidence that diagnosis rates increased rapidly (especially in young Black youths, often overtaking the rates in White youths). Twenty-one studies on diagnostic variation by socioeconomic or health insurance status and 8 studies on regional variation all demonstrated substantial differences.

Eighteen of 20 studies that compared diagnostic prevalence between 2 or more diagnostic criteria described a concurrent increase in potential cases with the broadening of criteria. Twenty-two studies reported a spectrum of ADHD-related behaviors showing that problems existed on a continuum, with ADHD on the extreme end in 7 studies and subthreshold behaviors on the other end displayed by a considerable proportion of young people in 8 studies, indicating a large reservoir of potentially diagnosable ADHD. This continuum was also described by a higher risk of adverse outcomes with increasing ADHD symptoms from subthreshold symptom levels to severe behaviors in 13 studies.

Evidence of expanding reservoirs attributed to the medicalization of behavior was found in 3 studies. Four of 5 phenotype change studies reported stable or declining ADHD symptoms in the population, making it unlikely that the expansion was associated with an actual increase in ADHD symptoms over time.

Sixteen studies that investigated diagnostic inaccuracies as a reason for variation reported potential underdiagnosis because of false-negative diagnosis and potential overdiagnosis because of false-positive diagnosis.

**Consistent Increases in ADHD Diagnosis Between 1989 and 2017**

Of the 45 studies included to answer question 2, 30 studies estimated change in diagnostic prevalence of ADHD over time, with 27 documenting increased trends and 3 observing a plateau in the early 2000s. Similar evidence came from studies that measured trends in annual diagnostic incidence or lifetime diagnostic prevalence, with nearly all of these studies (96.0%) confirming continuously increasing ADHD diagnoses.

---

**Figure 2. Risk of Bias (ROB) Assessment**

[Diagram showing risk of bias assessment with percentage of studies per ROB level]

The full results from the critical appraisals are found in eAppendix 5 in Supplement 1.
Many Additional Cases On the Milder End of the ADHD Spectrum

Twenty-five studies were included to answer question 3. Five studies reported that only a small proportion of all diagnosed youths displayed severe ADHD behaviors.5,36,132,138,152

Eleven studies used changes in impairment as a proxy for severity. Eight of these studies confirmed that impairment levels, adverse outcomes, and benefits of medication substantially

Table 2. Main Results Mapped to the 5-Question Framework*

| Type of evidence (No. of studies) | Theme (No. of studies) | Subtheme (No. of studies) | Main outcomes (No. of studies) |
|----------------------------------|------------------------|---------------------------|-------------------------------|
| Question 1. Is there potential for increased diagnosis (n = 104 studies) |
| Prevalence variations (68)       | By subgroup (48)       | Sex (25)                  | Lower diagnosis in girls than boys (23)5,35,47,54 |
|                                  |                        | SES or insurance status (21) | Higher diagnosis in lower SES (13)6,36,39,45,46,49,53,56-58 |
|                                  |                        | Race/ethnicity (21)        | Lower diagnosis in Black and Hispanic vs White youths (14)6,35-37,41,42,48,49,53,56,62,63,65,66 |
|                                  |                        | Relative age (12)          | Youngest children in class more likely to be diagnosed (11)22,160-177 |
|                                  |                        | Location/region (8)        | Large variations in diagnosis by region (8)170,33,35,56,59,79,80 |
|                                  |                        | Other (1)                 | Higher diagnosis and reported symptoms in larger classes (1)122 |
|                                  | By diagnosis (20)      | Diagnostic criteria (20)  | Broadening of criteria associated with increases in potential cases in comparisons between any DSM version and/or ICD-10 (18)141,20,52,79,93 |
|                                  |                        | Reservoir (44)            | Broadening of age of onset associated with minimal increases in potential cases (2)108,95 |
|                                  |                        | Medicalization (3)        | Society’s decreasing tolerance for different behavior associated with increased range of behavior diagnosed as abnormal (2)457,96 |
|                                  |                        | Phenotype changes (5)     | Mental health professionals from China and Indonesia rating same attention difficulties higher than mental health professionals from US and Japan (1)337 |
|                                  |                        | Diagnostic inaccuracy (16) | Potential over- and underdiagnosis occurring (6)1,64,65,101-103 |
|                                  |                        | Spectrum of disorder (22) | Continuous association between increasing symptoms and increased risk of various later adverse outcomes (13)100-120 |
|                                  |                        | Implications of extent of symptoms over time (13) | Percentage of youths with symptoms decreases with age (2)132,123 |
|                                  |                        | Subthreshold prevalence (8) | Many youths with subthreshold symptoms (6)108-110,115,121 |
| Question 2. Has diagnosis actually increased? (n = 45 studies) |
| Diagnosis (45)                   | Trend over time (45)   | Change in prevalence (30) | Increasing trend (27)1,2,5,21,34,35,41,44,46,50,61,66,74,130-144 until early 2000s (3)143,60,145 |
|                                  |                        | Change in incidence (12)  | Increasing trend (11)1,5,14,43,44,140,142,146-149 until 2007 (1)60 |
|                                  |                        | Change in lifetime prevalence (12) | Increasing trend (11)1,2,5,6,21,36,37,40,42,46,56,59,100 |
|                                  |                        | Stagnant in adolescents and increasing in children (1)108 |
| Question 3. Are additional cases subclinical or low risk? (n = 25 studies) |
| Severity of disorder (17) indicated by theme | Impairment levels (11) indicated by subtheme | Change in adverse outcomes over time (2) | Decreasing problems with increasing ADHD group (1)100 |
|                                  |                        | Difference in adverse outcomes by diagnostic criteria (9) | Broadening of diagnostic criteria and increasing of ADHD group associated with less impairment (5)79,83,86,88,93 |
|                                  |                        | Symptom severity (6) indicated by subtheme | Sample size too small to detect differences (4)84,87,94 |
|                                  |                        | Diagnostic criteria (1)   | No difference in severity between late and early-onset cases (1)93 |
| Level of symptoms (8)            | Clinically significant symptoms prevalence (8) by change over time (8) | Prevalence estimates of symptomatic ADHD remaining steady or slightly decreasing (6)21,20,91,98,99 |
|                                  |                        | Relative age effect increasing in later birth cohorts (2)170,75 |

(continued)
decreased with the expansion of the group of diagnosed youths. Six studies that confirmed stable or declining ADHD behaviors in youths over several decades supported this finding. Correspondingly, 2 studies on the relative age effect on ADHD diagnosis reported that the proportion of youngest children in class who received a diagnosis compared with older children had increased in more recent birth cohorts. In contrast, 3 studies that reported time trends of parent- or clinician-perceived severity of the disorder showed larger relative increases in more severe cases (which could be associated with a growing tendency to report the same behaviors as more severe).

### Substantial Increases in Pharmacological Treatment for ADHD Between 1971 and 2018

Of the 83 studies included to answer question 4, 64 showed an increasing percentage of youths being pharmacologically treated for ADHD. Three studies identified a plateau or decrease in this trend for preschool-aged children, with 2 studies indicating a general declining trend in youths in Germany who received treatment. Annual incident treatment rates were reported to be increasing in 5 studies and to be stable or without a clear trend in 4 studies, whereas 10 of 11 studies reported increasing trends in medication dispensing or sales.

### Benefits May Be Outweighed by Harms in Youth With Milder ADHD Symptoms Diagnosis

A total of 31 studies reported the consequences of diagnosis (question 5a). We focused on the benefits and harms for milder cases. Only 2 studies provided information on this group and both reported harms and found that the diagnostic label could have adverse social, psychological, and academic effects when compared with undiagnosed youths with similar behaviors.

Regarding the general benefits of a diagnosis (across the full spectrum of ADHD cases), 2 main themes emerged. First, in 14 studies, an ADHD diagnosis was shown to create a sense of

| Question 4. Have some additional cases been treated? (n = 83 studies) | Medication (83) | Trend over time (83) indicated by subtheme | Prevalent treatment rate (58) | Increasing trend (55) | Decreases in those younger than 6 years and increases in those older than 6 years (2) | Mostly decreasing trend (2) | Stable or variable rate (4) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| | Trend over time (83) indicated by subtheme | Incidence treatment rate (9) | Increasing trend (5) | Decreases in those younger than 6 years and increases in those older than 6 years (2) |
| | Medication use (11) | Increasing trend (10) | Increasing trend until 2004 in those younger than 6 years (1) |
| | Consultations in which ADHD medication is prescribed (10) | Increasing trend (9) | Increasing trend until 2004 in those younger than 6 years (1) |

| Question 5a. Might harms outweigh benefits of diagnosis? (n = 31 studies) | Potential benefits of diagnosis (15) | Empowered (14) through | Explanation for problems (11) | Increased legitimacy and validation (5) |
| --- | --- | --- | --- | --- |
| | | Increased understanding, sympathy, and reassurance (8) | Decreased guilt, blame, failure, and anger (6) |
| | | Increased control (6) | Decreased uncertainty; feeling of identity and belonging (3) |
| | | Increased self-esteem and confidence (3) | Expectation of solution (4) |
| | | Enabled (10) to | Support (10) | Increased ability to seek, receive, and accept support (10) |
| | Potential harms of diagnosis (29) | Disempowered (22) through | Excuse for problems (15) | Decreased responsibility for behaviors and problems (6) |
| | | Increased deflection from underlying problems (3) | No meaningful benefit from diagnosis or no change (10) |
| | Stigmatization (14) through | Permanent label and identity (14) | Enhanced prejudice, stereotypes, and judgment (14) | Increased feelings of isolation, exclusion, and shame (3) |
Table 2. Main Results Mapped to the 5-Question Framework* (continued)

| Type of evidence (No. of studies) | Theme (No. of studies) | Subtheme (No. of studies) | Main outcomes (No. of studies) |
|-----------------------------------|------------------------|--------------------------|--------------------------------|
| Outcomes of pharmacological treatment (120) | Academic (19) | Cognitive and motor functioning (4) | Improvements in commission errors only; all others unchanged (1) 241 |
| | | | Favorable outcomes in several aspects of cognition (1) 342 and motor skills (1) 343 |
| | | | No change after washout period (1) 239 |
| | Academic performance (15) | | Worse educational outcomes in treated vs rest of the population (1) 244 |
| | | | No treatment effect (3) 245, 247 |
| | | | Some small favorable outcomes in treated vs untreated youths (6) 246-253 |
| | | | Substantial improvement in treated vs untreated or less treated youths (2) 254, 255 |
| | | | Decrease in academic outcomes after increased medication treatment (1) 256 |
| | | | Potential harmful outcome, especially in youths with less severe symptoms (1) 246,b |
| | | | Medication treatment only beneficial for youths with more severe symptoms (1) 253,b |
| Accidents (12) | ED use and hospital admissions (5) | | Fewer hospital contacts in treated vs untreated youths, but outcomes smaller in later, larger diagnosed and treated cohorts (1) 150,b |
| | | | No change in hospital contacts in treated vs untreated periods and youths (2) 257, 25b |
| | | | Fewer hospital contacts during treated vs untreated periods (2) 357, 359 |
| | | | Worse health outcomes in treated vs rest of the population (1) 244 |
| | Injuries and poisoning (8) | | Lower risk of injuries in treated vs untreated youths (3) 259-261 and youths (2) 262, 263 |
| | | | No change in injuries (1) 264 or MVAs (1) 265 during treated vs untreated periods |
| | | | Increase in unintentional poisonings with ADHD medication (1) 266 |
| Cardiovascular (6) | Blood pressure and heart rate (2) | | No association of treatment with blood pressure (2) 267, 268 but with heart rate (1) 268 |
| | Safety (6) | | No association of treatment with severe cardiovascular events (3) 269-271 |
| | | | Increased risk of arrhythmia (1) 272 or any serious cardiac event (1) 273 |
| | | | Not enough statistical power to detect small differences (2) 274, 275, 276, 277 |
| Efficacy (30) | Symptom reduction (30) | | Substantial short-term symptom reduction for many (24) 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306 |
| | | | No symptom improvement after 48-hour washout period (1) 296 |
| | | | No long-term difference in treated vs untreated youths (3) 297, 298, 299, 300, 301, 302 |
| | | | Individuals with more severe symptoms at baseline showed greatest treatment response in the long term (5 years) (1) 303,b |
| Physical (14) | Activity (2) | | Lower levels of physical activity in treated vs untreated periods (1) 209 and youths (1) 201 |
| | Height (12) and weight (5) | | Growth delay (2) 297, 298 and decreased growth (6) 297, 298, 299, 300, 301, 302, 303, 304, 305, 306 |
| | | | No change observed and substantial heterogeneity (5) 297, 298, 300, 301, 302, 303, 304, 305, 306 |
| Psychological (20) | Other (2) | | Increased risk of psychosis (1) 311 and tics (1) 312 |
| | Substance abuse (12) | | No association of treatment with later substance abuse (4) 231-234 reduced risk (5) 317, 318, 319 |
| | | | and increased risk of stimulant abuse (4) 231-234 |
| | | | Prescription stimulant misuse or diversion in youths with or without ADHD (2) 231, 232 |
| | Suicidal behavior (6) | | No association of treatment with risk of suicidal behavior (2) 235, 236 reduced risk (3) 327, 328 and increased risk (1) 329 |
| Social and emotional (11) | Emotional (3) | | Increased risk of irritability with amphetamine treatment (1) 331 |
| | | | Mixed outcomes for various emotional behaviors with stimulant treatment (1) 332 |
| | | | Decrease in happiness after increased medication treatment (1) 332 |
| | Criminal behavior (3) | | Reduced risk of conviction and incarceration in treated vs untreated periods (1) 333 |
| | | | No change in risk of receiving driving citation for treated vs untreated periods (1) 334 |
| | | | Reduced risk of being charged with a crime in treated vs untreated youths, but effects were smaller in later, larger diagnosed and treated cohorts (1) 350,b |
| | Social impairment (2) | | Little change in social impairment in treated vs untreated period (1) 344 |
| | Quality of life (4) | | Potentially relevant improvements in some domains in treatment vs placebo group (1) 353 |
| | | | No treatment effect (3) 245-247 |
| | | | Quality of life (1) 245-247; no impact (1) 247 |
| | | | No change after washout period (1) 228 |
| | | | Favorable outcomes in several aspects of cognition (1) 242 and motor skills (1) 243 |
| | | | Decrease in academic outcomes after increased medication treatment (1) 256 |
| | | | Potential harmful outcome, especially in youths with less severe symptoms (1) 246,b |
| | | | Medication treatment only beneficial for youths with more severe symptoms (1) 253,b |
| Tolerability (29) | Adverse events (25) | | Low occurrence of mild AEs (2) 210, 211 |
| | | | Relatively common mild or moderate AEs (16) 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235 |
| | | | Young children more vulnerable to AEs (2) 215, 216 |
| | | | Reporting of AEs unsatisfactory (6) 217, 218, 219, 220, 221, 222 |
| | | | Serious AEs rare but difficult to determine from reported data (5) 217, 218, 219, 220, 221 |
| | | | Lack of methodologically sound research on which to base decisions (1) 217 |
| | | | Reduced risk of various outcomes reported some benefits of treatment (1) 349 |
| | | | Reduced risk of various outcomes (2) 350, 351 |
| | | | Lack of methodologically sound research on which to base decisions (1) 352 |
| | | | Longer treatment duration indicated better outcomes for various domains (1) 353 |
| | | | No long-term treatment effect for various functioning outcomes (3) 354, 355 |

* Full main results are presented in eAppendix 6 in Supplement 1.
  a Items refer specifically to the benefits and harms for young people with less severe ADHD behaviors.
empowerment for those involved. It provided a biomedical explanation for experienced problems, supporting a sense of legitimacy, accompanied by understanding and sympathy as well as decreased guilt, blame, and anger. Subsequently, this explanation could increase perceived control, with expectations of solutions, enhanced confidence, and a sense of belonging. Second, enablement was often experienced and was characterized by increased support accompanying a diagnosis of ADHD and by an enhanced ability to seek and accept help.

Two themes related to potential harms also emerged. First, in 22 studies, a biomedical view of difficulties was shown to be associated with disempowerment. By providing an excuse for problems, a decrease in responsibility by all involved can occur, often followed by inaction and stagnation. This view can also deflect from other underlying individual, social, or systemic problems, which can prompt a self-fulfilling prophecy, wherein the perceived inability to change reduces opportunities as well as promotes hopelessness and passiveness. This loss of control may be especially high when the diagnosis is used as a step toward coercing young people into correcting arguably problematic behaviors.

Second, 14 studies reported on stigmatization. The diagnosis can create an identity that enhances prejudice and judgment, which are associated with even greater feelings of isolation, exclusion, and shame.

Treatment | A total of 120 studies reported on the consequences of pharmacological treatment. Forty studies reported on the direct outcomes of pharmacological treatment of ADHD, including 2 studies on treatment efficacy stratified by severity of ADHD behaviors. These studies confirmed substantially greater treatment response in youths with more severe symptoms at baseline and diminished benefits in milder cases. None of the 29 studies that reported on direct harms of treatment differentiated between case severity.

Of the 85 studies on indirect outcomes of treatment, 3 studies reported on youths with less severe ADHD. Two of these articles suggested that treatment was only beneficial to academic outcomes in youths with severe symptoms, with 1 study reporting a potentially harmful outcome in milder cases. Another study found that the benefits of medication in reducing hospital contacts and criminal behavior were smaller in later birth cohorts for whom treatment prevalence was higher (thus likely expanding treatment to milder cases).

Twenty-four studies that reported the direct outcomes of medication across the spectrum of symptoms supported substantial short-term symptom reduction. However, only 3 studies reported long-term follow-up beyond active treatment, finding no difference in symptoms between youths who were treated and those who were untreated in later life, and another study found no difference in symptoms after a 48-hour washout period. In terms of harms, active treatment was commonly associated with mild and moderate adverse events and high discontinuation rates. Ten studies mentioned unsatisfactory reporting of harms.

Indirect treatment effects (across the spectrum of ADHD symptoms) were documented for diverse outcomes, including academic, cardiovascular, physical, psychological, social and emotional, and accidents. We found evidence of benefits for academic outcomes, injuries, hospital admissions, criminal behavior, and quality of life. In addition, harmful outcomes were evident for heart rate and cardiovascular events, growth, and weight. Risk for psychosis and tics, and stimulant misuse or poisoning. Treatment was associated with reduced physical activity in 2 studies. For suicidal behavior as well as emotional and social impairment, we could not find any favorable or unfavorable patterns.
The findings suggest that relatively large symptom reductions through medication translate to modest decreases in functional impairment at best while carrying risks. This ratio is likely worse for youth with milder ADHD in which large symptom reductions are impossible.

Discussion

To our knowledge, this study is the first systematic scoping review on overdiagnosis of ADHD in youths. We found evidence of overdiagnosis and overtreatment of ADHD. We confirmed a large reservoir of diagnosable ADHD, consistently increasing rates of ADHD diagnosis and treatment, and a large proportion of newly detected cases with milder symptoms (in which harms may outweigh smaller benefits of diagnosis and treatment). Furthermore, we found few studies that assessed symptom severity among extra cases diagnosed through expanded disease definitions as well as the balance of benefits and harms for these individuals, representing a critical evidence gap.

Implications of Findings

Our findings have implications for these individuals, who may be harmed by overdiagnosis and the adverse effects of medication during childhood, adolescence, and even adulthood. These findings are also relevant to the growing number of adults being newly diagnosed with ADHD and may be applicable to other conditions, such as autism.

Several important research questions emerged during this review. Larger studies need to be conducted to confirm whether the additional ADHD cases now being diagnosed have milder symptoms. Future research is also required to evaluate whether diagnosing and treating milder ADHD cases may carry net harm. To reduce health and educational inequities, resources must be shifted from the overdiagnosis and overtreatment of ADHD to the needs of youths with more severe symptoms and who are more likely to benefit, including those currently underdiagnosed. Our research focused on overdiagnosis, and we did not address the misdiagnosis and underdiagnosis of ADHD. Although they are outside of the scope of this study, misdiagnosis and underdiagnosis are important complementary issues in a broader discussion of the principles of “right” care and equitable use of health care resources.

We recommend that practitioners, parents, and teachers carefully weigh the potential benefits and harms that can accompany ADHD diagnosis and treatment, especially when identifying youths (or adults) with milder symptoms. For this group, the benefits of diagnosis and treatment may be considerably reduced or outweighed by harms.

An option to improve the balance of benefits to harm in practice may be to follow a stepped-diagnosis approach, as described by Batstra et al and Thomas et al. This approach incorporates the valid need for efficient diagnosis and treatment for severe cases as well as a watch-and-wait approach for borderline cases. It echoes management by active surveillance of low-risk prostate, breast, and thyroid cancers, in which overdiagnosis occurs frequently, and it ensures that resources are allocated where they are needed most and will be most valuable.

Strengths and Limitations

This study has several strengths. The 5-question framework enabled us to undertake a systematic scoping review, in accordance with international standards, to synthesize a large, heterogeneous set of studies. We undertook a critical appraisal of the included studies that allowed us to evaluate the quality of the evidence collected globally over many decades. Previous analyses focused on specific aspects of ADHD overdiagnosis, such as the existence of a relative age effect, differences between diagnosis and phenotype trends, or outcomes of medication. Although they contributed important evidence to the literature, these earlier studies were unable to draw overall conclusions on overdiagnosis of ADHD, which we were able to do.

This study also has several limitations. First, despite the inclusion of studies from many countries over a long period, these findings may not be applicable to all demographic groups. Given
the scope of this study, we restricted the evidence for questions 4 and 5 to pharmacological treatment of ADHD, which is the most common and controversial treatment. Second, this review is limited by the availability and quality of evidence. Although our confidence in the outcomes for questions 2 and 4 is high, many studies included for questions 1, 3, and 5 were at high risk of bias. Third, parents or teachers were often the sole reporters of potentially subjective measures (e.g., symptom severity, quality of life, and consequences of diagnosis). This lack of self-reported data means that it is unknown whether benefits and harms may have been reported differently by the youths themselves.

Conclusions

In this systematic scoping review, we found convincing evidence of ADHD overdiagnosis and overtreatment in children and adolescents. Despite an abundance of research in the field of ADHD, gaps in evidence remain. In particular, high-quality studies on the long-term benefits and harms of diagnosing and treating ADHD in young people with milder symptoms are needed to inform safe and equitable practice and policy.

ARTICLE INFORMATION

Accepted for Publication: February 13, 2021.
Published: April 12, 2021. doi: 10.1001/jamanetworkopen.2021.5335
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Kazda L et al. JAMA Network Open.
Corresponding Author: Luise Kazda, MPH, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Edward Ford Building (A27), Room 124, Sydney, NSW 2006, Australia (luise.kazda@sydney.edu.au).
Author Affiliations: Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia (Kazda, Bell, McGeechan, Barratt); Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland, Australia (Thomas, Sims).
Author Contributions: Ms Kazda had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Kazda, Bell, Thomas, Barratt.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Kazda, Barratt.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: McGeechan.
Obtained funding: Barratt.
Administrative, technical, or material support: Kazda.
Supervision: Kazda, Bell, Thomas, Barratt.
Conflict of Interest Disclosures: Ms Kazda reported receiving grants from the Australian government National Health and Medical Research Council (NHMRC) during the conduct of the study. Dr Bell reported receiving grants from the NHMRC during the conduct of the study and grants from the NHMRC outside the submitted work. Dr Thomas reported receiving support from the NHMRC outside the submitted work. Dr McGeechan reported receiving grants from the NHMRC during the conduct of the study. Ms Sims reported receiving other support from the Australian government Research Training Program Scholarship outside the submitted work. Dr Barratt reported receiving grants from the NHMRC during the conduct of the study and serving as a member of the Scientific Committee of Preventing Overdiagnosis International Conferences. No other disclosures were reported.
Funding/Support: This study was supported by program grant 11I3532 and Centre for Research Excellence grant 1104136 from Wiser Healthcare, funded by the NHMRC.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Justin Clark, BA, Bond University, assisted with the search strategy development. Mr Clark received no financial compensation for his contribution. Benjamin Trevitt, MPH, MBBS, University of Sydney, assisted with the full text reviews of papers. Dr Trevitt received financial compensation as a research assistant for this study.

REFERENCES
1. Rydell M, Lundström S, Gillberg C, Lichtenstein P, Larsson H. Has the attention deficit hyperactivity disorder phenotype become more common in children between 2004 and 2014? trends over 10 years from a Swedish general population sample. J Child Psychol Psychiatry. 2018;59(8):863-871. doi:10.1111/jcpp.12882
2. Chien IC, Lin CH, Chou YJ, Chou P. Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996-2005: a national population-based study. Soc Psychiatry Psychiatr Epidemiol. 2012;47(12):1885-1890. doi:10.1007/s00127-012-0501-1
3. Giacobini M, Medin E, Ahnemark E, Russo LJ, Carlqvist P. Prevalence, patient characteristics, and pharmacological treatment of children, adolescents, and adults diagnosed with ADHD in Sweden. J Atten Disord. 2018;22(1):3-13. doi:10.1177/1087054714554617
4. Conrad P, Bergey MR. The impending globalization of ADHD: notes on the expansion and growth of a medicalized disorder. Soc Sci Med. 2014;122:31-43. doi:10.1016/j.socscimed.2014.10.019
5. Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry. 2014;53(5):446-488. doi:10.1097/00004583-201309000-00011
6. Xu G, Strathearn L, Liu B, Yang B, Bao W. Twenty-year trends in diagnosed attention-deficit/hyperactivity disorder among US children and adolescents, 1997-2016. JAMA Netw Open. 2018;1(4):e181471. doi:10.1001/jamanetworkopen.2018.1471
7. Coon ER, Quinonez RA, Moyer VA, Schroeder AR. Overdiagnosis: how our compulsion for diagnosis may be harming children. Pediatrics. 2014;134(5):1013-1023. doi:10.1542/peds.2014-1778
8. Batstra L, Frances A. DSM-5 further inflates attention deficit hyperactivity disorder. J Nerv Ment Dis. 2012;200(6):486-488. doi:10.1097/NMD.0b013e318257c4b6
9. Batstra L, Hadders-Algra M, Nieweg E, Van Tol D, Pijl SJ, Frances A. Childhood emotional and behavioral problems: reducing overdiagnosis without risking undertreatment. Dev Med Child Neurol. 2012;54(6):492-494. doi:10.1111/j.1469-8749.2011.04176.x
10. Fabiano F, Haslam N. Diagnostic inflation in the DSM: A meta-analysis of changes in the stringency of psychiatric diagnosis from DSM-III to DSM-5. Clin Psychol Rev. 2020;80:101889. doi:10.1016/j.cpr.2020.101889
11. Bruchmüller K, Margraf J, Schneider S. Is ADHD diagnosed in accord with diagnostic criteria? Overdiagnosis and influence of client gender on diagnosis. J Consult Clin Psychol. 2012;80(1):128-138. doi:10.1037/a0026582
12. Taylor E. Attention deficit hyperactivity disorder: overdiagnosed or diagnoses missed? Arch Dis Child. 2017;102(4):376-379. doi:10.1136/archdischild-2016-310487
13. Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ. 2015;350:g7773. doi:10.1136/bmj.g7773
14. Davies L, Petitti DB, Martin L, Woo M, Lin JS. Defining, estimating, and communicating overdiagnosis in cancer screening. Ann Intern Med. 2018;169(1):36-43. doi:10.7326/M18-0694
15. Merten EC, Cwik JC, Margraf J, Schneider S. Overdiagnosis of mental disorders in children and adolescents (in developed countries). Child Adolesc Psychiatry Ment Health. 2017;11:5. doi:10.1186/s13034-016-0140-5
16. Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med. 2011;171(9):831-837. doi:10.1001/archinternmed.2011.178
17. Johansson M, Jørgensen KJ, Brodersen J. Harms of screening for abdominal aortic aneurysm: is there more to life than a 0.46% disease-specific mortality reduction? Lancet. 2016;387(10015):308-310. doi:10.1016/S0140-6736(15)00472-9
18. Bell KJL, Doust J, Glassiou P, et al. Recognizing the potential for overdiagnosis: are high-sensitivity cardiac troponin assays an example? Ann Intern Med. 2019;170(4):259-261. doi:10.7326/M18-2645
19. Haslam N. Concept creep: psychology’s expanding concepts of harm and pathology. Psychol Inq. 2016;27(1):1-17. doi:10.1080/1047840X.2016.1082418
20. McKeown RE, Holbrook JR, Danielson ML, Cuffe SP, Wolaich ML, Visser SN. The impact of case definition on attention-deficit/hyperactivity disorder prevalence estimates in community-based samples of school-aged children. *J Am Acad Child Adolesc Psychiatry*. 2015;54(1):53-61. doi:10.1016/j.jaac.2014.10.014

21. Safer DJ. Is ADHD really increasing in youth? *J Atten Disord*. 2018;22(2):107-115. doi:io.1177/1087054718786757

22. Layton TJ, Barnett ML, Hicks TR, Jena AB. Attention-deficit-hyperactivity disorder and month of school enrollment. *N Engl J Med*. 2018;379(22):2122-2130. doi:10.1056/NEJMoa1806828

23. Brodersen J, Schwartz LM, Heneghan C, O’Sullivan JW, Aronson JK, Woloshin S. Overdiagnosis: what it is and what it isn’t. *BMJ Evid Based Med*. 2018;23(1):1-3. doi:10.1136/ebmed-2017-110886

24. Rogers WA, Mintzker Y. Getting clearer on overdiagnosis. *J Eval Clin Pract*. 2016;22(4):580-587. doi:10.1111/jep.12556

25. Thomas R, Mitchell GK, Batstra L. Attention-deficit/hyperactivity disorder: are we helping or harming? *BMJ*. 2013;347:f6172. doi:10.1136/bmj.f6172

26. Layton TJ, Barnett ML, Hicks TR, Jena AB. Attention-deficit-hyperactivity disorder and month of school enrollment. *N Engl J Med*. 2018;379(22):2122-2130. doi:10.1056/NEJMoa1806828

27. Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Chapter 11: scoping reviews (2020 version). In: Aromataris E, Munn Z, eds. *JBI Manual for Evidence Synthesis*. JBI; 2020.

28. Kazda L, Bell K, Thomas R, McGeenah K, Barratt A. Evidence of potential overdiagnosis and overtreatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents: protocol for a scoping review. *BMJ Open*. 2019;9(11):e032327. doi:10.1136/bmjopen-2019-032327

29. Carter SM, Degeling C, Doust J, Barratt A. A definition and ethical evaluation of overdiagnosis. *J Med Ethics*. 2016;42(1):705-714. doi:10.1136/medethics-2015-102928

30. Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Chapter 11: scoping reviews (2020 version). In: Aromataris E, Munn Z, eds. *JBI Manual for Evidence Synthesis*. JBI; 2020.

31. Akmatov MK, Steffen A, Holstiege J, Hering R, Schulz M, Bätzing J. Trends and regional variations in the administrative prevalence of attention-deficit/hyperactivity disorder among children and adolescents in Germany. *Sci Rep*. 2018;8(1):17029. doi:10.1038/s41598-018-35048-5

32. Brault MC, Lacourse É. Prevalence of prescribed attention-deficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children: 1994-2007. *Can J Psychiatry*. 2012;57(2):93-101. doi:10.1177/070674371205700206

33. Centers for Disease Control and Prevention (CDC). Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder—United States, 2003. *MMWR Morb Mortal Wkly Rep*. 2005;54(34):842-847.

34. Centers for Disease Control and Prevention (CDC). Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children—United States, 2003 and 2007. *MMWR Morb Mortal Wkly Rep*. 2010;59(44):1439-1443.

35. Centers for Disease Control and Prevention (CDC). Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder—United States, 2003. *MMWR Morb Mortal Wkly Rep*. 2005;54(34):842-847.

36. Collins KP, Cleary SD. Racial and ethnic disparities in parent-reported diagnosis of ADHD: National Survey of Children’s Health (2003, 2007, and 2011). *J Clin Psychiatry*. 2016;77(1):52-59. doi:10.4088/JCP.14m09364

37. Cuffe SP, Moore CG, McKeown RE. Prevalence and correlates of ADHD symptoms in the national health interview survey. *J Atten Disord*. 2005;9(2):392-401. doi:10.1177/1087054705280413

38. Danielson ML, Visser SN, Gleason MM, Peacock G, Claussen AH, Blumberg SJ. A national profile of attention-deficit hyperactivity disorder diagnosis and treatment among US children aged 2 to 5 years. *J Dev Behav Pediatr*. 2017;38(7):455-464. doi:10.1097/DBP.0000000000000477

39. Davidovitch M, Koren G, Fund N, Shrem M, Porath A. Challenges in defining the rates of ADHD diagnosis and treatment: trends over the last decade. *BMC Pediatr*. 2017;17(1):218. doi:10.1186/s12887-017-0971-0

40. Fairman KA, Peckham AM, Sclar DA. Diagnosis and treatment of ADHD in the United States: update by gender and race. *J Atten Disord*. 2020;24(1):10-19. doi:10.1177/1087054716688534
42. Hvey JM, Olson JM, McCormick C, Cates GL. Teachers' perceptions of the incidence and management of attention-deficit hyperactivity disorder. *Appl Neuropsychol*. 2005;12(2):120-127. doi:10.1207/s15324826an1202_7

43. Hire AJ, Ashcroft DM, Springate DA, Steinke DT. ADHD in the United Kingdom: regional and socioeconomic variations in incidence rates among children and adolescents (2004-2013). *J Atten Disord*. 2018;22(2):134-142. doi:10.1177/108705471663441

44. Huang CL, Chu CC, Cheng TJ, Weng SF. Epidemiology of treated attention-deficit/hyperactivity disorder (ADHD) across the lifespan in Taiwan: a nationwide population-based longitudinal study. *PLoS One*. 2014;9(4):e95014. doi:10.1371/journal.pone.0095014

45. Huss M, Hölling H, Kurth BM, Schlack R. How often are German children and adolescents diagnosed with ADHD? prevalence based on the judgment of health care professionals: results of the German health and examination survey (KiGGS). *Eur Child Adolesc Psychiatry*. 2008;17(suppl 1):S2-S8. doi:10.1007/s00787-008-1006-z

46. Prasad V, West J, Kendrick D, Sayal K. Attention-deficit/hyperactivity disorder: variation by socioeconomic deprivation. *Arch Dis Child*. 2019;104(8):802-805. doi:10.1136/archdischild-2017-314470

47. Robison LM, Skaar TL, Sclar DA, Galin RS. Is attention deficit hyperactivity disorder increasing among girls in the US? trends in diagnosis and the prescribing of stimulants. *CNS Drugs*. 2002;16(2):129-137. doi:10.2165/00023210-200216020-00005

48. Rowland AS, Umbach DM, Stallone L, Naftel AJ, Bohlig EM, Sandler DP. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. *Am J Public Health*. 2002;92(2):231-234. doi:10.2105/AJPH.92.2.231

49. Schneider H, Eisenberg D. Who receives a diagnosis of attention-deficit/hyperactivity disorder in the United States elementary school population? *Pediatrics*. 2006;117(4):e601-e609. doi:10.1542/peds.2005-1308

50. Schubert I, Köster I, Lehmkuhl G. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insures of the AOK Health Insurance Co in the German State of Hesse, 2000-2007. Article in German and English. *Dtsch Arztebl Int*. 2010;107(36):615-621. doi:10.3288/arztebl.2010.0615

51. Siegel CE, Laska EM, Wanderling JA, Hernandez JC, Levenson RB. Prevalence and diagnosis rates of childhood ADHD among racial-ethnic groups in a public mental health system. *Psychiatr Serv*. 2016;67(2):199-205. doi:10.1176/appi.ps.201400364

52. Skounti M, Philalithis A, Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. *Eur J Pediatr*. 2007;166(2):117-123. doi:10.1007/s00431-006-0299-5

53. Zablotsky B, Black LJ, Maenner MJ, et al. Prevalence and trends of developmental disabilities among children in the United States. 2009-2017. *Pediatrics*. 2019;144(4):10. doi:10.1542/peds.2019-0811

54. Froehlich TE, Lanphear BP, Epstein JN, Barbareis WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. *Arch Pediatr Adolesc Med*. 2007;161(9):857-864. doi:10.1001/archpedi.161.9.857

55. Morley CP. The effects of patient characteristics on ADHD diagnosis and treatment: a factorial study of family physicians. *BMC Fam Pract*. 2010;11:11. doi:10.1186/1471-2296-11-11

56. Akinbami LJ, Liu X, Pastor PN, Reuben CA. Attention deficit hyperactivity disorder among children aged 5-17 years in the United States, 1998-2009. *NCHS Data Brief*. 2011;(70):1-8.

57. Allan J, Harwood V. Medicus interruptus in the behaviour of children in disadvantaged contexts in Scotland. *Br J Social Educ*. 2014;35(3):431-431. doi:10.1080/01425692.2013.776933

58. Anderson J. Reported Diagnosis and Prescription Utilization Related to Attention Deficit Hyperactivity Disorder in Children Ages 5-17, 2008-2015. Agency for Healthcare Research and Quality; 2001.

59. Brownell MD, Yogendran MS. Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychostimulant treatment rates. *Can J Psychiatry*. 2001;46(3):264-272. doi:10.1177/070674370104600307

60. Holden SE, Jenkins-Jones S, Poole CD, Morgan CL, Coghill D, Currie CJ. The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). *Child Adolesc Psychiatry Ment Health*. 2013;7(1):34. doi:10.1186/1753-2000-7-34

61. Nyarko KA, Grosse SD, Danielson ML, Holbrook JR, Visser SN, Shapira SK. Treated prevalence of attention-deficit/hyperactivity disorder increased from 2009 to 2015 among school-aged children and adolescents in the United States. *J Child Adolesc Psychopharmacol*. 2017;27(8):731-734. doi:10.1089/cap.2016.0196

62. Bax AC, Bard DE, Cuffe SP, McKeown RE, Wolraich ML. The association between race/ethnicity and socioeconomic factors and the diagnosis and treatment of children with attention-deficit hyperactivity disorder. *J Dev Behav Pediatr*. 2019;40(2):81-91. doi:10.1097/DBP.0000000000000626
63. Morgan PL, Staff J, Hillemeier MM, Farkas G, Maczuga S. Racial and ethnic disparities in ADHD diagnosis from kindergarten to eighth grade. *Pediatrics*. 2013;132(1):85-93. doi:10.1542/peds.2012-2390

64. Owens J, Jackson H. Attention-deficit/hyperactivity disorder severity, diagnosis, and later academic achievement in a national sample. *Soc Sci Res*. 2017;61:251-265. doi:10.1016/j.ssresearch.2016.06.018

65. Coker TR, Elliott MN, Toomey SL, et al. Racial and ethnic disparities in ADHD diagnosis and treatment. *Pediatrics*. 2016;138(3):e20160407. doi:10.1542/peds.2016-0407

66. Getahun D, Jacobsen SJ, Fassett MJ, Chen W, Demissie K, Rhoads GG. Recent trends in childhood attention-deficit/hyperactivity disorder. *JAMA*. 2016;315(3):282-288. doi:10.1001/jama.2015.18335

67. Reyes N, Baumgardner DJ, Simmons DH, Buckingham W. The potential for sociocultural factors in the diagnosis of ADHD in children. *WMJ*. 2013;112(1):13-17.

68. Bonati M, Cartabia M, Zanetti M, et al. Age level vs grade level for the diagnosis of ADHD and neurodevelopmental disorders. *Eur Child Adolesc Psychiatry*. 2018;27(9):1171-1180. doi:10.1007/s00787-018-1180-6

69. Elder TE. The importance of relative standards in ADHD diagnoses: evidence based on exact birthdates. *J Health Econ*. 2010;29(5):641-656. doi:10.1016/j.jhealeco.2010.06.003

70. Evans WN, Morrill MS, Parente ST. Measuring inappropriate medical diagnosis and treatment in survey data: the case of ADHD among school-age children. *J Health Econ*. 2010;29(5):657-673. doi:10.1016/j.jhealeco.2010.07.005

71. Hallfors L, Tillander A, Lundholm C, et al. Relative immaturity and ADHD: findings from nationwide registers, parent- and self-reports. *J Child Psychol Psychiatry*. 2014;55(8):897-904. doi:10.1111/jcpp.12229

72. Holland J, Sayal K. Relative age and ADHD symptoms, diagnosis and medication: a systematic review. *Eur Child Adolesc Psychiatry*. 2019;28(11):1417-1429. doi:10.1007/s00787-018-1229-6

73. Karlstad Ø, Furu K, Stoltenberg C, Håberg SE, Bakken IJ. ADHD treatment and diagnosis in relation to children's birth month: nationwide cohort study from Norway. *Scand J Public Health*. 2017;45(4):343-349. doi:10.1177/1403494817708080

74. Morrow RL, Garland EJ, Wright JM, Macure M, Taylor S, Dormuth CR. Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children. *CMAJ*. 2012;184(7):755-762. doi:10.1503/cmaj.111619

75. Sayal K, Chudal R, Hinkka-Yli-Salomäki S, Joelsson P, Sourander A. Relative age within the school year and diagnosis of attention-deficit hyperactivity disorder: a nationwide population-based study. *Lancet Psychiatry*. 2017;4(11):868-875. doi:10.1016/S2215-0366(17)30394-2

76. Schwandt H, Wuppermann A. The youngest get the pill: ADHD misdiagnosis in Germany, its regional correlates and international comparison. *Labour Econ*. 2016;43:72-86. doi:10.1016/j.labeco.2016.05.018

77. Whitely M, Raven M, Timimi S, et al. Attention deficit hyperactivity disorder late birthdate effect common in both high and low prescribing international jurisdictions: a systematic review. *J Child Psychol Psychiatry*. 2019;60(4):380-391. doi:10.1111/jcpp.12991

78. Dalsgaard S, Humlum MK, Nielsen HS, Simonsen M. Relative standards in ADHD diagnoses: the role of specialist behavior. *Econ Lett*. 2012;117(3):663-665. doi:10.1016/j.econlet.2012.08.008

79. Baumgaertel A, Wolaich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. *J Am Acad Child Adolesc Psychiatry*. 1995;34(5):629-638. doi:10.1097/00004583-199505000-00015

80. Döpfner M, Breuer D, Wille N, Erhart M, Ravens-Sieberer U; BELLA Study Group. How often do children meet ICD-10/DSM-IV criteria of attention deficit/hyperactivity disorder and hyperkinetic disorder? parent-based prevalence rates in a national sample-results of the BELLA study. *Eur Child Adolesc Psychiatry*. 2008;17(suppl 1):S9-S10. doi:10.1007/s00787-008-1007-y

81. Ghanizadeh A. Agreement between Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and the proposed DSM-V attention deficit hyperactivity disorder diagnostic criteria: an exploratory study. *Compr Psychiatry*. 2013;54(1):7-10. doi:10.1016/j.comppsych.2012.06.001

82. Lahey BB, Applegate B, McBurnett K, et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. *Am J Psychiatry*. 1994;151(11):1673-1685. doi:10.1176/ajp.151.11.1673

83. Lahey BB, Loebel R, Stoughamer-Loeber M, et al. Comparison of DSM-III and DSM-III-R diagnoses for prepubertal children: changes in prevalence and validity. *J Am Acad Child Adolesc Psychiatry*. 1990;29(4):620-626. doi:10.1097/00004583-199007000-00017
Lahey BB, Pelham WE, Chronis A, et al. Predictive validity of ICD-10 hyperkinetic disorder relative to DSM-IV attention-deficit/hyperactivity disorder among younger children. *J Child Psychol Psychiatry*. 2006;47(5):472-479. doi:10.1111/j.1469-7610.2005.01590.x

Lee SI, Schachar RJ, Chen SX, et al. Predictive validity of DSM-IV and ICD-10 criteria for ADHD and hyperkinetic disorder. *J Child Psychol Psychiatry*. 2008;49(1):70-78. doi:10.1111/j.1469-7610.2007.01784.x

Leung PW, Luk SL, Ho TP, Taylor E, Mak FL, Bacon-Shone J. The diagnosis and prevalence of hyperactivity in Chinese schoolboys. *Br J Psychiatry*. 1996;168(4):486-496. doi:10.1192/bjp.168.4.486

Newcorn JH, Halperin JM, Healey JM, et al. Are ADDH and ADHD the same or different? *J Am Acad Child Adolesc Psychiatry*. 1989;28(5):734-738. doi:10.1097/00004583-198909000-00015

Newcorn JH, Halperin JM, Schwartz S, et al. Parent and teacher ratings of attention-deficit hyperactivity disorder symptoms: implications for case identification. *J Dev Behav Pediatr*. 1994;15(2):86-91. doi:10.1097/00004703-199404000-00004

Peyre H, Hoertel N, Cortese S, et al. Attention-deficit/hyperactivity disorder symptom expression: a comparison of individual age at onset using item response theory. *J Clin Psychiatry*. 2014;75(4):386-392. doi: 10.4088/JCP.13m08638

Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. *Int J Epidemiol*. 2014;43(2):434-442. doi:10.1093/ije/dyt261

Thomas R, Sanders S, Doust J, Beller E, Glassiou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. *Pediatrics*. 2015;135(4):e994-e1001. doi:10.1542/peds.2014-3482

Vande Voort JL, He JP, Jameson ND, Merikangas KR. Impact of the DSM-5 attention-deficit/hyperactivity disorder age-of-onset criterion in the US adolescent population. *J Am Acad Child Adolesc Psychiatry*. 2014;53(7):736-744. doi:10.1016/j.jaac.2014.03.005

Polanczyk G, Caspi A, Houts R, Kollins SH, Rohde LA, Moffitt TE. Implications of extending the ADHD age-of-onset criterion to age 12: results from a prospectively studied birth cohort. *J Am Acad Child Adolesc Psychiatry*. 2010;49(3):210-216. doi:10.1097/00004583-201003000-00004

Sibley MH, Rohde LA, Swanson JM, et al; Multimodal Treatment Study of Children With ADHD (MTA) Cooperative Group. Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. *Am J Psychiatry*. 2018;175(2):140-149. doi:10.1176/appi.ajp.2017.17030298

Malacrida C. Medicalization, ambivalence and social control: mothers’ descriptions of educators and ADD/ADHD. *Health (London)*. 2004;8(1):61-80. doi:10.1177/1363459304038795

Mann EM, Ikeda Y, Mueller CW, et al. Cross-cultural differences in rating hyperactive-disruptive behaviors in children. *Am J Psychiatry*. 1992;149(11):1539-1542. doi:10.1176/ajp.149.11.1539

Sawyer MG, Reece CE, Sawyer ACP, Johnson SE, Lawrence D. Has the prevalence of child and adolescent mental disorders in Australia changed between 1998 and 2013 to 2014? *J Am Acad Child Adolesc Psychiatry*. 2018;57(5):343-350.es. doi:10.1016/j.jaac.2018.02.012

Sellers R, Maughan B, Pickles A, Thapar A, Collishaw S. Trends in parent- and teacher-rated emotional, conduct and ADHD problems and their impact in prepubertal children in Great Britain: 1999-2008. *J Child Psychol Psychiatry*. 2015;56(1):49-57. doi:10.1111/jcpp.12273

Wolraich ML, Hannah JN, Pinnock TY, Baumgaertel A, Brown J. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. *J Am Acad Child Adolesc Psychiatry*. 1996;35(3):319-324. doi:10.1097/00004583-199603000-00013

Madsen KB, Ravn MH, Arnfred J, Olsen J, Rask CU, Obel C. Characteristicsofundiagnosedchildrenwithparent-reportedADHDbehaviour. *Eur Child Adolesc Psychiatry*. 2018;27(2):149-158. doi:10.1007/s00787-017-1029-4

Okumura Y, Yamasaki S, Ando S, et al. Psychosocial burden of undiagnosed persistent ADHD symptoms in 12-year-old children: a population-based birth cohort study. *J Atten Disord*. 2021;25(5):636-645. doi:10.1177/1087054719837746
104. Loughran SB. Agreement and stability of teacher rating scales for assessing ADHD in preschoolers. Early Child Educ J. 2003;30(4):247-253. doi:10.1023/A:1023391708850

105. Rowland AS, Umbach DM, Catoe KE, et al. Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results. Can J Psychiatry. 2001;46(10):931-940. doi:10.1177/070674370104601005

106. Fabiano GA, Pelham WE Jr, Majumdar A, et al. Elementary and middle school teacher perceptions of attention-deficit/hyperactivity disorder prevalence. Child Youth Care Forum. 2013;42(2):87-99. doi:10.1007/s10566-013-9194-1

107. Foreman DM, Ford T. Assessing the diagnostic accuracy of the identification of hyperkinetic disorders following the introduction of government guidelines in England. Child Adolesc Psychiatry Ment Health. 2008;2(1):32. doi:10.1186/1753-2000-2-32

108. Balázs J, Keresztény A. Subthreshold attention deficit hyperactivity in children and adolescents: a systematic review. Eur Child Adolesc Psychiatry. 2014;23(6):393-408. doi:10.1007/s00787-013-0514-7

109. Biederman J, Fitzgerald M, Kirova AM, Woodworth KY, Biederman I, Faraone SV. Further evidence of morbidity and dysfunction associated with subsyndromal ADHD in clinically referred children. J Clin Psychiatry. 2018;79(5):1m11870. doi:10.4088/JCP.17m11870

110. Cho SC, Kim BN, Kim JW, et al. Full syndrome and subthreshold attention-deficit/hyperactivity disorder in a Korean community sample: comorbidity and temperament findings. Eur Child Adolesc Psychiatry. 2009;18(7):447-457. doi:10.1007/s00787-009-0755-7

111. Fergusson DM, Boden JM, Horwood LJ. Classification of behavior disorders in adolescence: scaling methods, predictive validity, and gender differences. J Abnorm Psychol. 2010;119(4):699-712. doi:10.1037/a0018610

112. Fergusson DM, Horwood LJ. Predictive validity of categorically and dimensionally scored measures of disruptive childhood behaviors. J Am Acad Child Adolesc Psychiatry. 1995;34(4):477-485. doi:10.1097/00004583-199504000-00015

113. Fergusson DM, Lynskey MT, Horwood LJ. Attentional difficulties in middle childhood and psychosocial outcomes in young adulthood. J Child Psychol Psychiatry. 1997;38(6):633-644. doi:10.1111/j.1469-7610.1997.tb01690.x

114. Hong SB, Dwyer D, Kim JW, et al. Subthreshold attention-deficit/hyperactivity disorder is associated with functional impairments across domains: a comprehensive analysis in a large-scale community study. Eur Child Adolesc Psychiatry. 2014;23(8):627-636. doi:10.1007/s00787-013-0501-z

115. Kirova AM, Kelberman C, Storch B, et al. Are subsyndromal manifestations of attention deficit hyperactivity disorder morbid in children? a systematic qualitative review of the literature with meta-analysis. Psychiatry Res. 2019;274:75-90. doi:10.1016/j.psychres.2019.02.003

116. Merrell C, Sayal K, Tymms P, Kasim A. A longitudinal study of the association between inattention, hyperactivity and impulsivity and children’s academic attainment at age 11. Learn Individ Differ. 2017;53:156-161. doi:10.1016/j.lindiff.2016.04.003

117. Norén Selinus E, Molero Y, Lichtenstein P, et al. Subthreshold and threshold attention deficit hyperactivity disorder symptoms in childhood: psychosocial outcomes in adolescence in boys and girls. Acta Psychiatr Scand. 2016;134(6):533-545. doi:10.1111/acps.12655

118. Sayal K, Washbrook E, Propper C. Childhood behavior problems and academic outcomes in adolescence: longitudinal population-based study. J Am Acad Child Adolesc Psychiatry. 2015;54(5):360-368.2. doi:10.1016/j.jaac.2015.02.007

119. Schmiedeler S, Schneider W. Attention-deficit hyperactivity disorder (ADHD) in the early years: diagnostic issues and educational relevance. Clin Child Psychol Psychiatry. 2014;19(3):460-475. doi:10.1177/1359104513489979

120. Whalen CK, Jamner LD, Henker B, Delfino RJ, Lozano JM. The ADHD spectrum and everyday life: experience sampling of adolescent moods, activities, smoking, and drinking. Child Dev. 2002;73(1):209-227. doi:10.1111/1467-8624.00401

121. Larsson H, Anckarsater H, Råstam M, Chang Z, Lichtenstein P. Childhood attention-deficit hyperactivity disorder as an extreme of a continuous trait: a quantitative genetic study of 8,500 twin pairs. J Child Psychol Psychiatry. 2012;53(1):73-80. doi:10.1111/j.1469-7610.2011.02467.x

122. Lecendreux M, Konofal E, Cortese S, Faraone SVA. A 4-year follow-up of attention-deficit/hyperactivity disorder in a population sample. J Clin Psychiatry. 2015;76(6):712-719. doi:10.4088/JCP.14m09555
123. Lecendreux M, Silverstein M, Konofal E, Cortese S, Faraone SVA. A 9-year follow-up of attention-deficit/hyperactivity disorder in a population sample. *J Clin Psychiatry*. 2019;80(3):18m12642. doi:10.4088/JCP.18m12642

124. Haslam N, Williams B, Prior M, Haslam R, Graetz B, Sawyer M. The latent structure of attention-deficit/hyperactivity disorder: a taxometric analysis. *Aust NZ J Psychiatry*. 2006;40(8):639-647. doi:10.1080/j.1440-1614.2006.01863.x

125. Hudziak JJ, Heath AC, Madden PF, et al. Latent class and factor analysis of DSM-IV ADHD: a twin study of female adolescents. *J Am Acad Child Adolesc Psychiatry*. 1998;37(8):848-857. doi:10.1097/00004583-199808000-00015

126. Levy F, Hay DA, McStephen M, Wood C, Waldman I. Attention-deficit/hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. *J Am Acad Child Adolesc Psychiatry*. 1997;36(6):737-744. doi:10.1097/00004583-199706000-00009

127. Lubke GH, Hudziak JJ, Derks EM, van Bisterveldt TCEM, Boomsma DI. Maternal ratings of attention problems in ADHD: evidence for the existence of a continuum. *J Am Acad Child Adolesc Psychiatry*. 2009;48(11):1085-1093. doi:10.1097/CHI.0b013e3181ba3dbb

128. Marcus DK, Barry TD. Does attention-deficit/hyperactivity disorder have a dimensional latent structure? A taxometric analysis. *J Abnorm Psychol*. 2011;120(2):427-442. doi:10.1037/a0021405

129. McLennan JD. Understanding attention deficit hyperactivity disorder as a continuum. *Can Fam Physician*. 2016;62(12):979-982.

130. Atladottir HO, Gyllenberg D, Langridge A, et al. The increasing prevalence of reported diagnoses of childhood psychiatric disorders: a descriptive multinational comparison. *Eur Child Adolesc Psychiatry*. 2015;24(2):173-183. doi:10.1007/s00787-014-0553-8

131. Fulton BD, Scheffler RM, Hinshaw SP. State variation in increased ADHD prevalence: links to NCLB school accountability and state medication laws. *Psychiatr Serv*. 2015;66(10):1074-1082. doi:10.1176/appi.ps.201400145

132. Garfield CF, Dorsey ER, Zhu S, et al. Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010. *Acad Pediatr*. 2012;12(2):110-116. doi:10.1016/j.acap.2012.01.003

133. Hoagwood KE, Kelleher K, Zima BT, Perrin JM, Bilder S, Crystal S. Ten-year trends in treatment services for children with attention deficit hyperactivity disorder enrolled in Medicaid. *Health Aff (Millwood)*. 2016;35(7):1266-1270. doi:10.1377/hlthaff.2015.423

134. Langner I, Haug U, Scholle O, Lindemann C, Schröder C, Riedel O. Potential explanations for increasing methylphenidate use in children and adolescents with attention-deficit/hyperactivity disorder in Germany from 2004 to 2013. *J Clin Psychopharmacol*. 2019;39(1):39-45. doi:10.1097/JCP.0000000000000980

135. Robison LM, Sclar DA, Skaer TL, Galin RS. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. *Clin Pediatr (Phila)*. 1999;38(4):209-217. doi:10.1097/00003295-199904000-00003

136. Song I, Lee MS, Lee EK, Shin JY. Patient and provider characteristics related with prescribing of ADHD medication: nationwide health insurance claims database study in Korea. *Asia Pac Psychiatry*. 2018;10(1). doi:10.1111/appy.12289

137. Song I, Shin JY. Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011. *Epidemiol Health*. 2016;38:e2016045. doi:10.4178/epih.e2016045

138. Song M, Dieckmann NF, Nigg JT. Addressing discrepancies between ADHD prevalence and case identification estimates among U.S. children utilizing NSCH 2007-2012. *J Atten Disord*. 2019;23(14):1691-1702. doi:10.1177/1087054718799930

139. Toh S. Datapoints: trends in ADHD and stimulant use among children, 1993-2003. *Psychiatr Serv*. 2006;57(8):1091. doi:10.1176/ps.2006.57.8.1091

140. Vasiliadis HM, Diallo FB, Rochette L, et al. Temporal trends in the prevalence and incidence of diagnosed ADHD in children and young adults between 1999 and 2012 in Canada: a data linkage study. *Can J Psychiatry*. 2017;62(12):818-826. doi:10.1177/0706743717714468

141. Wang LJ, Lee SY, Yuan SS, et al. Prevalence rates of youths diagnosed with and medicated for ADHD in a nationwide survey in Taiwan from 2000 to 2011. *Epidemiol Psychiatr Sci*. 2017;26(6):624-634. doi:10.1136/europsp-2017-011721

142. Winterstein AG, Gerhard T, Shuster J, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. *Ann Pharmacother*. 2008;42(1):24-31. doi:10.1345/aph.1K143
143. Yoshida M, Obara T, Kikuchi S, et al. Drug prescriptions for children with ADHD in Japan: a study based on health insurance claims data between 2005 and 2015. J Atten Disord. 2020;24(2):175-191. doi: 10.1177/1087054719843179

144. Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, Zarin DA. Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 1999;153(12):1257-1263. doi: 10.1001/archpedi.153.12.1257

145. Sclar DA, Robison LM, Bowen KA, Schmidt LV, Oganov AM. Attention-deficit/hyperactivity disorder among children and adolescents in the United States: trend in diagnosis and use of pharmaceutical by gender. Clin Pediatr (Phila). 2012;51(6):584-589. doi: 10.1177/0009922812439621

146. Huang CL, Wang JI, Ho CH. Trends in incidence rates of diagnosed attention-deficit/hyperactivity disorder (ADHD) over 12 years in Taiwan: a nationwide population-based study. Psychiatry Res. 2020;284:112792. doi: 10.1016/j.psychres.2020.112792

147. Mohr Jensen C, Steinhausen HC. Time trends in incidence rates of diagnosed attention-deficit/hyperactivity disorder across 16 years in a nationwide Danish registry study. J Clin Psychiatry. 2015;76(3):e334-e341. doi: 10.4088/JCP.14m09094

148. Pérez-Crespo L, Canals-Sans J, Suades-González E, Guxens M. Temporal trends and geographical variability of the prevalence and incidence of attention deficit/hyperactivity disorder diagnoses among children in Catalonia, Spain. Sci Rep. 2020;10(1):6397. doi: 10.1038/s41598-020-63342-8

149. Štuhec M, Švab V, Locatelli I. Prevalence and incidence of attention-deficit/hyperactivity disorder diagnoses among children in Slovenia. J Child Adolesc Psychopharmacol. 2015;25(6):525-533. doi: 10.1089/cap.2012.0111

150. Dalsgaard S, Nielsen HS, Simonsen M. Consequences of ADHD medication use for children's outcomes. J Health Econ. 2014;37:137-151. doi: 10.1016/j.jhealeco.2014.05.005

151. Santosh PJ, Taylor E, Swanson J, et al. Refining the diagnoses of inattention and overactivity syndromes: a reanalysis of the multimodal treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clin Neurosci Res. 2005;5(5-6):307-314. doi: 10.1017/s1473444205143

152. Donfrancesco R, Marano A, Calderoni D, et al. Prevalence of severe ADHD: an epidemiological study in the Italian regions of Tuscany and Latium. Epidemiol Psychiatr Sci. 2015;24(6):525-533. doi: 10.1136/epspsc-2015-000523

153. Bachmann CJ, Wijlaars LP, Kalverdijk LJ, et al. Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012. Eur Neuropsychopharmacol. 2017;27(5):484-493. doi: 10.1016/j.euroneuro.2017.03.002

154. Barczyk ZA, Rucklidge JJ, Eggleston M, Mulder RT. Psychotropic medication prescription rates and trends for New Zealand children and adolescents 2008-2016. J Child Adolesc Psychopharmacol. 2020;30(2):87-96. doi: 10.1089/cap.2019.0032

155. Beau-Lejdstrom R, Douglas I, Evans SJW, Smeeth L. Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open. 2016;6(6):e010508. doi: 10.1136/bmjopen-2015-010508

156. Boland F, Galvin R, Reulbach U, et al. Psychostimulant prescribing trends in a paediatric population in Ireland: a national cohort study. BMC Pediatr. 2015;15:118. doi: 10.1186/1471-2431-15-118

157. Burcu M, Zito JM, Metcalfe L, Underwood H, Safer DJ. Trends in stimulant medication use in commercially insured youths and adults, 2010-2014. JAMA Psychiatry. 2016;73(9):992-993. doi: 10.1001/jamapsychiatry.2016.1182

158. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord. 2007;10(4):335-342. doi: 10.1177/1087054707299597

159. Dalsgaard S, Nielsen HS, Simonsen M. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study. J Child Adolesc Psychopharmacol. 2013;23(7):432-439. doi: 10.1089/cap.2012.0111

160. Fogelman Y, Vinker S, Guy N, Kahan E. Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period. CNS Drugs. 2003;17(12):915-919. doi: 10.2165/000223210-200317120-00005

161. Fullerton CA, Epstein AM, Frank RG, Normand SL, Fu CX, McGuire TG. Medication use and spending trends among children with ADHD in Florida’s Medicaid program, 1996-2005. Psychiatr Serv. 2012;63(2):115-121. doi: 10.1176/appi.ps.201100095
162. Furu K, Karlstad Ø, Zoega H, et al. Utilization of stimulants and atomoxetine for attention-deficit/hyperactivity disorder among 5.4 million children using population-based longitudinal data. *Basic Clin Pharmacol Toxicol*. 2017;120(4):373-379. doi:10.1111/bcpt.12724

163. Grimmsson T, Himmel W. The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany. *Eur J Clin Pharmacol*. 2021;77(1):107-115. doi:10.1007/s00228-020-03294-3

164. Gumy C, Huissoud T, Dubois-Arber F. Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics. *J Atten Disord*. 2010;14(3):267-272. doi:10.1177/1087054709356386

165. Habel LA, Schaefer CA, Levine P, Bhat AK, Elliott G. Treatment with stimulants among youths in a large California health plan. *J Child Adolesc Psychopharmacol*. 2005;15(1):62-67. doi:10.1089/cap.2005.15.62

166. Hodgkins P, Sasané R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. *Clin Ther*. 2011;33(2):188-203. doi:10.1016/j.clinthera.2011.03.001

167. Hugtenburg JG, Heerdink ER, Egberts AC. Increased psychotropic drug consumption by children in the Netherlands during 1995-2001 is caused by increased use of methylphenidate by boys. *Eur J Clin Pharmacol*. 2004;60(5):377-379. doi:10.1007/s00228-004-0765-9

168. Jaber L, Rigler S, Shuper A, Diamond G. Changing epidemiology of methylphenidate prescriptions in the community: a multifactorial model. *J Atten Disord*. 2017;21(14):1143-1150. doi:10.1177/1087054714528044

169. Johansen ME, Matic K, McAlearney AS. Attention deficit hyperactivity disorder medication use among teens and young adults. *J Adolesc Health*. 2015;57(2):192-197. doi:10.1016/j.jadohealth.2015.04.009

170. Karanges EA, Stephenson CP, McGregor IS. Longitudinal trendsin the dispensing of psychotropic medications in Australia from 2009-2012: focus on children, adolescents and prescriber specialty. *Aust NZ J Psychiatry*. 2014;48(10):917-931. doi:10.1177/0004867414538675

171. Knellwolf A-L, Deligne J, Chiarotti F, et al. Prevalence and patterns of methylphenidate use in French children and adolescents. *Eur J Clin Pharmacol*. 2008;64(3):311-317. doi:10.1007/s00228-007-0401-6

172. Lillemoen PK, Kjosavik SR, Hunskår S, Ruths S. Prescriptions for ADHD medication, 2004-08. *Tidsskr Nor Laegeforen*. 2012;132(16):1856-1860. doi:10.4045/tidsskr.11.1270

173. Lopez-Leon S, Lopez-Gomez MI, Warner B, Ruiter-Lopez L. Psychotropic medication in children and adolescents in the United States in the years 2004 vs 2014. *Daru*. 2018;26(1):5-10. doi:10.1007/s40199-018-0204-6

174. Man KKC, Ip P, Hsia Y, et al. ADHD drug prescribing trend is increasing among children and adolescents in Hong Kong. *J Atten Disord*. 2017;21(14):1161-1168. doi:10.1177/1087054714536047

175. McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. *BMC Pediatr*. 2012;12:78. doi:10.1186/1471-2431-12-78

176. Morkemo R, Patten S, Queenan J, Barber D. Recent trends in the prescribing of ADHD medications in Canadian primary care. *J Atten Disord*. 2020;24(2):301-308. doi:10.1177/1087054717720719

177. Olfson M, Gameroff MJ, Marcus SC, Jensen PS. National trends in the treatment of attention deficit hyperactivity disorder. *Am J Psychiatry*. 2003;160(6):1071-1077. doi:10.1176/appi.ajp.160.6.1071

178. Raman SR, Man KKC, Bahmanyar S, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. *Lancet Psychiatry*. 2018;5(10):824-835. doi:10.1016/S2215-0366(18)30293-1

179. Renoux C, Shin JY, Dell’Aniello S, Fergusson D, Sissa S. Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. *Br J Clin Pharmacol*. 2016;82(3):858-868. doi:10.1111/bcp.13000

180. Romano E, Baillargeon RH, Wu HX, Robaey P, Tremblay RE. Prevalence of methylphenidate use and change over a two-year period: a nationwide study of 2- to 11-year-old Canadian children. *J Pediatr*. 2002;141(1):71-75. doi:10.1067/mjp.2002.325399

181. Safer DJ, Krager JM. Trends in medication treatment of hyperactive school children: results of six biannual surveys. *Clin Pediatr (Phila)*. 1983;22(7):500-504. doi:10.1177/00099288302207007

182. Safer DJ, Krager JM. Trends in medication therapy for hyperactivity: national and international perspectives. *Adv Learn Behav Disabil*. 1984;3:125-149.

183. Safer DJ, Krager JM. The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools. *Pediatrics*. 1994;94(4 pt 1):462-464.
184. Salmelainen P. Trends in the prescribing of stimulant medication for the treatment of attention deficit hyperactivity disorder in children and adolescents in New South Wales. N S W Public Health Bull. 2002;13(suppl 1):1-65. doi:10.1071/NB02S01

185. Trip AM, Visser ST, Kalverdijk LJ, de Jong-van den Berg LTW. Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol. 2009;67(4):466-468. doi:10.1111/j.1365-2125.2009.03373.x

186. Valentine J, Zubrick S, Sly P. National trends in the use of stimulant medication for attention deficit hyperactivity disorder. J Paediatr Child Health. 1996;32(3):223-227. doi:10.1111/j.1440-1754.1996.tb01558.x

187. Vinker S, Vinker R, Elhayany A. Prevalence of methylphenidate use among Israeli children: 1998-2004. Clin Drug Investig. 2006;26(3):161-167. doi:10.2165/00044011-200626030-00006

188. Vuori M, Koski-Pirilä A, Martikainen JE, Saastamoinen L. Gender- and age-stratified analyses of ADHD medication use in children and adolescents in Finland using population-based longitudinal data, 2008-2018. Scand J Public Health. 2020;48(3):303-307. doi:10.1177/1403494820901426

189. Wang LJ, Lee SY, Yuan SS, et al. Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan. Pharmacoepidemiol Drug Saf. 2016;25(1):45-53. doi:10.1002/pds.3907

190. Yoon EY, Cohn L, Rocchini A, Kershaw D, Clark SJ. Clonidine utilization trends for Medicaid children. Clin Pediatr (Phila). 2012;51(10):950-955. doi:10.1177/0009922812441661

191. Zetterqvist J, Asherson P, Halldner L, Långström N, Larsson H. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr Scand. 2013;128(1):70-77. doi:10.1111/acps.12004

192. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283(8):1025-1030. doi:10.1001/jama.283.8.1025

193. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry. 2006;163(4):579-585. doi:10.1176/ajp.2006.163.4.579

194. Davis DW, Feygin Y, Creel L, et al. Longitudinal trends in the diagnosis of attention-deficit/hyperactivity disorder and stimulant use in preschool children on Medicaid. J Pediatr. 2019;207:185-191.e1. doi:10.1016/j.jpeds.2018.10.062

195. Zuvekas SH, Vitiello B. Stimulant medication use in children: a 12-year perspective. Am J Psychiatry. 2012;169(2):160-166. doi:10.1176/appi.ajp.2011.11030387

196. Janols LO, Liliemark J, Klintberg K, von Knorring AL. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007. Nord J Psychiatry. 2009;63(6):508-516. doi:10.3109/08039480903154534

197. van den Ban E, Souverein P, Swaab H, van Engeland H, Heerdink R, Egberts T. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006. J Child Adolesc Psychopharmacol. 2010;20(1):55-61. doi:10.1089/cap.2008.0153

198. Jick H, Kaye JA, Black C. Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK. Br J Gen Pract. 2004;54(502):345-347.

199. Prosser B, Lambert MC, Reid R. Psychostimulant prescription for ADHD in new South Wales: a longitudinal perspective. J Atten Disord. 2015;19(4):284-292. doi:10.1177/1087054714553053

200. Prosser B, Reid R. Changes in use of psychostimulant medication for ADHD in South Australia (1999-2006). Aust N Z Psychiatry. 2009;43(4):340-347. doi:10.1080/0004867090271129

201. Alessi-Severini S, Biscontri RG, Collins DM, Sareen J, Enns MW. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry. 2012;57(1):52-58. doi:10.1177/070674371205700109

202. Bruckner TA, Hodgson A, Mahoney CB, Fulton BD, Levine P, Scheffler RM. Health care supply and county-level variation in attention-deficit hyperactivity disorder prescription medications. Pharmacoepidemiol Drug Saf. 2012;21(4):442-449. doi:10.1002/pds.2264

203. Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002-2010. Pediatrics. 2012;130(1):23-31. doi:10.1542/peds.2011-2879

204. Hollingworth SA, Nissen LM, Stathis SS, Siskind DJ, Varghese JMN, Scott JG. Australian national trends in stimulant dispensing: 2002-2009. Aust N Z J Psychiatry. 2011;45(4):332-336. doi:10.3109/00048674.2010.543413
205. Öner O, Yilmaz ES, Karadağ H, et al. ADHD medication trends in Turkey: 2009-2013. J Atten Disord. 2017;21(4):1192-1197. doi:10.1177/1087054714523129

206. Ponizovsky AM, Marom E, Fitoussi I. Trends in attention deficit hyperactivity disorder drugs consumption, Israel, 2005-2012. Pharmacoepidemiol Drug Saf. 2014;23(5):534-538. doi:10.1002/pds.3604

207. Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff (Millwood). 2007;26(2):450-457. doi:10.1377/hlthaff.26.2.450

208. Štuhec M, Locatelli I, Švab V. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective. J Child Adolesc Psychopharmacol. 2015;25(3):254-259. doi:10.1089/cap.2014.0071

209. Treceño C, Martín Arias LH, Sáinz M, et al. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiol Drug Saf. 2012;21(4):435-441. doi:10.1002/pds.2348

210. Pottegård A, Bjerregaard BK, Glintborg D, Hallas J, Moreno SI. The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective. Eur J Clin Pharmacol. 2012;68(10):1443-1450. doi:10.1007/s00228-012-1265-y

211. Girand HL, Litkowiec S, Sohn M. Attention-deficit/hyperactivity disorder and psychotropic polypharmacy prescribing trends. Pediatrics. 2020;146(1):e20192832. doi:10.1542/peds.2019-2832

212. Thomas CP, Conrad P, Casler R, Goodman E. Trends in the use of psychotropic medications among adolescents, 1994 to 2001. Psychiatr Serv. 2006;57(1):63-69. doi:10.1176/appi.ps.57.1.63

213. Chirdkiatgumchai V, Xiao H, Fredstrom BK, et al. National trends in psychotropic medication use in young children: 1994-2009. Pediatrics. 2013;132(4):615-623. doi:10.1542/peds.2013-1546

214. Damico JS, Augustine LE. Social considerations in the labeling of students as attention deficit hyperactivity disordered. Semin Speech Lang. 1995;16(4):259-273. doi:10.1055/s-2008-1064126

215. Klasen H. A name, what's in a name? the medicalization of hyperactivity, revisited. Harv Rev Psychiatry. 2000;7(6):334-344. doi:10.3109/hrp.7.6.334

216. Moore DA, Russell AE, Arnell S, Ford TJ. Educators' experiences of managing students with ADHD: a qualitative study. Child Care Health Dev. 2017;43(4):489-498. doi:10.1111/cch.12448

217. Rogalin MT, Nencini A. Consequences of the "attention-deficit/hyperactivity disorder" (ADHD) diagnosis. An investigation with education professionals. Psychol Stud (Mysore). 2015;60(1):41-49. doi:10.1007/s12646-014-0288-0

218. Andersson Frondelius I, Ranjbar V, Danielsson L. Adolescents' experiences of being diagnosed with attention deficit hyperactivity disorder: a phenomenological study conducted in Sweden. BMJ Open. 2019;9(8):e031570. doi:10.1136/bmjopen-2019-031570

219. Carr-Fanning K, McGuckin C. The powerless or the empowered? stakeholders' experiences of diagnosis and treatment for attention-deficit hyperactivity disorder in Ireland. Ir J Psychol Med. 2018;35(3):203-212. doi:10.1017/ipm.2018.13

220. Hamed AM, Kauer AJ, Stevens HE. Why the diagnosis of attention deficit hyperactivity disorder matters. Front Psychiatry. 2015;6:168. doi:10.3389/fpsyt.2015.00168

221. Meza Ji, Monroy M, Ma R, Mendoza-Denton R. Stigma and attention-deficit/hyperactivity disorder: negative perceptions and anger emotional reactions mediate the link between active symptoms and social distance. Atten Defic Hyperact Disord. 2019;11(4):373-382. doi:10.1007/s12402-019-00302-x

222. Wienen AW, Sluiter MN, Thoutenhoofd E, de Jonge P, Batstra L. The advantages of an ADHD classification from the perspective of teachers. Eur J Spec Needs Educ. 2019;34(5):649-662. doi:10.1080/08856257.2019.1580838

223. Comstock E. The rhetorical construction of the AD/HD subject: managing the self. J Lang Identity Educ. 2015;14(1):1-18. doi:10.1080/15348458.2015.988566

224. Dryer R, Kiernan MJ, Tyson GA. The effects of diagnostic labelling on the implicit theories of attention-deficit/hyperactivity disorder held by health professionals. Behav Change. 2006;23(3):177-185. doi:10.1375/bech.23.3.177

225. Singh I. A disorder of anger and aggression: children's perspectives on attention deficit/hyperactivity disorder in the UK. Soc Sci Med. 2011;73(6):889-896. doi:10.1016/j.socscimed.2011.03.049

226. Cornell-Ruiz S, Hendricks B. Effects of labeling and ADHD behaviors on peer and teacher judgments. J Educ Res. 1993;86(6):349-355. doi:10.1080/00220671.1993.9941228
248. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? results from a population-based study. J Dev Behav Pediatr. 2007;28(4):274-287. doi:10.1097/DBP.Ob013e3180cabc28

249. Kortekaas-Rijlaarsdam AF, Luman M, Sonuga-Barke E, Oosterlaan J. Does methylphenidate improve academic performance? a systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2019;28(2):155-164. doi:10.1007/s00787-018-1106-3

250. Langberg JM, Becker SP. Does long-term medication use improve the academic outcomes of youth with attention-deficit/hyperactivity disorder? Clin Child Fam Psychol Rev. 2012;15(3):215-233. doi: 10.1007/s10567-012-0117-8

251. Prasad V, Brogan E, Mulvaney C, Grainge M, Stanton W, Sayal K. How effective are drug treatments for children with ADHD at improving on-task behaviour and academic achievement in the school classroom? a systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2013;22(4):203-216. doi:10.1007/s00787-012-0346-x

252. Scheffler RM, Brown TT, Fulton BD, Hinshaw SP, Hinshaw SP, Levine P, Stone S. Positive association between attention-deficit/hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics. 2009;123(5):1273-1279. doi:10.1542/peds.2008-1597

253. Zoëga H, Rothman KJ, Huybrechts KF, et al. A population-based study of stimulant drug treatment of ADHD and academic progress in children. Pediatrics. 2012;130(1):e53-e62. doi:10.1542/peds.2011-3493

254. Jangmo A, Stålhandske A, Chang Z, et al. Attention-deficit/hyperactivity disorder, school performance, and effect of medication. J Am Acad Child Adolesc Psychiatry. 2019;58(4):423-432. doi:10.1016/j.jaac.2018.11.014

255. Keilow M, Holm A, Fallesen P. Medical treatment of attention deficit/hyperactivity disorder (ADHD) and children's academic performance. PLoS One. 2018;13(11):e0207905. doi:10.1371/journal.pone.0207905

256. Currie J, Stabile M, Jones L. Do stimulant medications improve educational and behavioral outcomes for children with ADHD? J Health Econ. 2014;37:58-69. doi:10.1016/j.jhealeco.2014.05.002

257. Leibson CL, Barbaresi WJ, Ransom J, et al. Emergency medication use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment. Ambul Pediatr. 2006;6(1):45-53. doi:10.1016/j.ampeds.2005.08.005

258. van den Ban E, Souverein P, Meijer W, et al. Association between ADHD drug use and injuries among children and adolescents. Eur Child Adolesc Psychiatry. 2014;23(2):95-102. doi:10.1007/s00787-013-0432-8

259. Dalsgaard S, Leckman JF, Mortensen PB, Nielsen HS, Simonsen M. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015;2(8):702-709. doi:10.1016/S2215-0366(15)00271-0

260. Raman SR, Marshall SW, Haynes K, Gaynes BN, Naftel AJ, Stürmer T. Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design. Inj Prev. 2013;19(3):164-170. doi:10.1136/injuryprev-2012-040483

261. Ruiz-Goikoetxea M, Cortese S, Aznarez-Sanado M, et al. Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;84:63-71. doi:10.1016/j.neubiorev.2017.11.007

262. Perry BA, Archer KR, Song Y, et al. Medication therapy for attention deficit/hyperactivity disorder is associated with lower risk of fracture: a retrospective cohort study. Osteoporos Int. 2016;27(7):2223-2227. doi:10.1007/s00198-016-3547-1

263. Shem-Tov S, Chodick G, Weitzman D, Koren G. The association between attention-deficit hyperactivity disorder, injuries, and methylphenidate. Glob Pediatr Health. 2019;6:X19845920. doi:10.1177/2333794X19845920

264. Mikolajczyk R, Horn J, Schmidt N, Langner I, Lindemann C, Garbe E. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. JAMA Pediatr. 2015;169(4):391-395. doi:10.1001/jamapediatrics.2014.3275

265. Winterstein AG, Li Y, Gerhard T, Linden S, Shuster JJ. Medication use for ADHD and the risk of driving citations and crashes among teenage drivers: a population-based cohort study. J Atten Disord. 2020; 1087054720915768:1087054720915768. doi:10.1177/1087054720915768

266. Levine M, Froberg B, Ruha AM, et al. Assessing the toxicity and associated costs among pediatric patients admitted with unintentional poisonings of attention-deficit/hyperactivity disorder drugs in the United States. Clin Toxicol (Phila). 2013;51(3):147-150. doi:10.3109/15563650.2013.772623
267. Landgren M, Nasic S, Johnson M, Lövli T, Holmgren D, Fernell E. Blood pressure and anthropometry in children treated with stimulants: a longitudinal cohort study with an individual approach. *Neuropsychiatr Dis Treat*. 2017;13:499-506. doi:10.2147/NDT.S123526

268. Vitelli B, Elliott GR, Swanson JM, et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. *Am J Psychiatry*. 2012;169(2):167-177. doi:10.1176/appi.ajp.2011.11110705

269. Cooper WD, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. *N Engl J Med*. 2011;365(20):1896-1904. doi:10.1056/NEJMoal110212

270. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. *Pediatrics*. 2011;127(6):1102-1110. doi:10.1542/peds.2010-3371

271. Winterstein AG, Gerhard T, Kubilis P, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. *BMJ*. 2012;345:e4627. doi:10.1136/bmj.e4627

272. Shin JY, Roughhead EE, Park BJ, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. *BMJ*. 2016;353:i2550. doi:10.1136/bmj.i2550

273. Dalgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. *J Child Adolesc Psychopharmacol*. 2014;24(6):302-310. doi:10.1089/cap.2014.0020

274. Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review. *BMC Cardiovasc Disord*. 2012;12:41. doi:10.1186/1471-2261-12-41

275. Catalá-López F, Hutton B, Núñez-Beltrán A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. *PLoS One*. 2017;12(7):e0180355. doi:10.1371/journal.pone.0180355

276. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents—meta-analysis and meta-regression analysis. *Psychopharmacology (Berl)*. 2007;194(2):197-209. doi:10.1007/s00213-007-0840-x

277. Connor DF. Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treatment. *J Dev Behav Pediatr*. 2002;23(1)(suppl):S1-S9. doi:10.1097/00004703-200202001-00002

278. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry*. 2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4

279. Gayleard JL, Mychailyszyn MP. Atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology. *Atten Defic Hyperact Disord*. 2017;9(3):149-160. doi:10.1007/s12402-017-0216-y

280. Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. *J Am Acad Child Adolesc Psychiatry*. 2014;53(2):153-173. doi:10.1016/j.jaaps.2013.11.009

281. Keen D, Hadjiyanni I. ADHD in children and adolescents. *BMJ Clin Evid*. 2011;2011:0312.

282. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. *Health Technol Assess*. 2006;10(23):iii-iv, xiii-146. doi:10.3310/hta10230

283. Klassen A, Miller A, Raina P, Lee SK, Olsen L. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. *Can J Psychiatry*. 1999;44(10):1007-1016. doi:10.1177/070674379904401007

284. Malà CR, Cortese S, Caya A, et al. Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD. *J Atten Disord*. 2017;21(1):3-13. doi:10.1177/1087054714559643

285. Maneeton B, Maneeton N, Likhitsathian S, et al. Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials. *Drug Des Dev Ther*. 2015;9:1927-1936. doi:10.2147/DDDT.S79071

286. Moen MD, Keam SJ. Dexamphetamine extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder. *CNS Drugs*. 2009;23(12):1057-1083. doi:10.2165/11201140-000000000-00000

287. Otasowie J, Castells X, Ehimare UP, Smith CH. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev*. 2014;(9):CD006997. doi:10.1002/14651858.CD006997.pub2
288. Parker J, Wales G, Chalhoub N, Harpin V. The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials. *Psychol Res Behav Manag*. 2013;6:87-99. doi:10.2147/PRBM.S49114

289. Punja S, Shamseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev*. 2016;2:CD009996. doi:10.1002/14651858.CD009996.pub2

290. Riera M, Castells X, Tobias A, Cunill R, Blanco L, Capellà D. Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients. *Psychopharmacology (Berl)*. 2017;234(17):2657-2671. doi:10.1007/s00213-017-4662-1

291. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? a meta-analysis. *CMAJ*. 2001;165(11):1475-1488.

292. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. *J Am Acad Child Adolesc Psychiatry*. 2014;53(2):174-187. doi:10.1016/j.jaac.2013.11.005

293. Sibley MH, Kuriyan AB, Evans SW, Waxmonsky JG, Smith BH. Pharmacological and psychosocial treatments for adolescents with ADHD: an updated systematic review of the literature. *Clin Psychol Rev*. 2014;34(3):218-232. doi:10.1016/j.cpr.2014.02.001

294. Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). *Cochrane Database Syst Rev*. 2015;(11):CD009885. doi:10.1002/14651858.CD009885.pub2

295. Valdizán-Usón JR, Cánovas-Martínez A, De Lucas-Taracena MT, et al. Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. *Neuropsychiatr Dis Treat*. 2013;9:211-218. doi:10.2147/NDT.S35836

296. Schweren L, Hoekstra P, van Lieshout M, et al. Long-term effects of stimulant treatment on ADHD symptoms, social-emotional functioning, and cognition. *Psychol Med*. 2019;49(2):217-223. doi:10.1017/S0033291718000545

297. Swanson JM, Arnold LE, Molina BSG, et al; MTA Cooperative Group. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. *J Child Psychol Psychiatry*. 2017;58(6):663-678. doi:10.1111/jcpp.12684

298. van Lieshout M, Luman M, Twisk JW, et al. A 6-year follow-up of a large European cohort of children with attention-deficit/hyperactivity disorder-combined subtype: outcomes in late adolescence and young adulthood. *Eur Child Adolesc Psychiatry*. 2016;25(9):1007-1017. doi:10.1007/s00787-016-0820-y

299. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. *J Am Acad Child Adolesc Psychiatry*. 2004;43(5):559-567. doi:10.1097/00004583-200405000-00009

300. Butte NF, Treuth MS, Voigt RG, Llorente AM, Heird WC. Stimulant medications decrease energy expenditure and physical activity in children with attention-deficit/hyperactivity disorder. *J Pediatr*. 1999;135(2 pt 1):203-207. doi:10.1016/S0022-3476(99)70023-5

301. Bowling A, Davison K, Haneuse S, Beardslee W, Miller DP. ADHD medication, dietary patterns, physical activity, and BMI in children: a longitudinal analysis of the ECLS-K study. *Obesity (Silver Spring)*. 2017;25(10):1802-1808. doi:10.1002/oby.21949

302. Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. *Int Clin Psychopharmacol*. 2016;31(2):93-99. doi:10.1097/YIC.0000000000000109

303. Zhang H, Du M, Zhuang S. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. *Neuropediatrics*. 2010;41(2):55-59. doi:10.1055/s-0030-1261893

304. Díez-Suárez A, Vallejo-Valdivielso M, Marín-Méndez JJ, de Castro-Manglano P, Soutullo CA. Weight, height, and body mass index in patients with attention-deficit/hyperactivity disorder treated with methylphenidate. *J Child Adolesc Psychopharmacol*. 2017;27(8):723-730. doi:10.1089/cap.2016.0150

305. Faraoone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. *J Am Acad Child Adolesc Psychiatry*. 2008;47(9):994-1009. doi:10.1097/CHI.0b013e31817e0ea7

306. Lisska MC, Rivkees SA. Daily methylphenidate use slows the growth of children: a community based study. *J Pediatr Endocrinol Metab*. 2003;16(5):711-718. doi:10.1515/JPEM.2003.16.5.711
Poulton A. Growth on stimulant medication; clarifying the confusion: a review. *Arch Dis Child.* 2005;90(8):801-806. doi:10.1136/adc.2004.056952

Powell SG, Frydenberg M, Thomsen PH. The effects of long-term medication on growth in children and adolescents with ADHD: an observational study of a large cohort of real-life patients. *Child Adolesc Psychiatry Ment Health.* 2015;9:50. doi:10.1186/s13034-015-0082-3

Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. *Pediatrics.* 2014;134(4):e935-e944. doi:10.1542/peds.2014-0428

Zachor DA, Roberts AW, Hodgens JB, Isaacs JS, Merrick J. Effect of long-term psychostimulant medication on growth of children with ADHD. *Res Dev Disabil.* 2006;27(2):162-174. doi:10.1016/j.ridd.2004.12.004

Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. *N Engl J Med.* 2019;380(12):1128-1138. doi:10.1056/NEJMoal1813751

Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. *Am J Psychiatry.* 2008;165(5):597-603. doi:10.1176/appi.ajp.2007.07091486

Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. *JAMA Psychiatry.* 2013;70(7):740-749. doi:10.1001/jamapsychiatry.2013.1273

Huss M, Pousta F, Lehmkuhl G, Lehmkuhl U. No increase in long-term risk for nicotine use disorders after treatment with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD): evidence from a non-randomised retrospective study. *J Neural Transm (Vienna).* 2008;115(2):335-339. doi:10.1007/s00702-008-0872-3

Setlik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. *Pediatrics.* 2009;124(3):875-880. doi:10.1542/peds.2008-0931

Davies M, Coughtrie A, Layton D, Shakir SA. Use of atomoxetine and suicidal ideation in children and adolescents: results of an observational cohort study within general practice in England. *Eur Psychiatry.* 2017;39:11-16. doi:10.1016/j.eurpsy.2016.06.005

Man KKC, Coghill D, Chan EW, et al. Association of risk of suicide attempts with methylphenidate treatment. *JAMA Psychiatry.* 2017;74(10):1048-1055. doi:10.1001/jamapsychiatry.2017.2183

Chang Z, Quinn PD, O’Reilly L, et al. Medication for attention-deficit/hyperactivity disorder and risk for suicide attempts. *Biol Psychiatry.* 2020;88(6):452-458. doi:10.1016/j.biopsych.2019.12.003
328. Chen Q, Sjölander A, Runeson B, D’Onofrio BM, Lichtenstein P, Larsson H. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. *BMJ*. 2014;348:g3769. doi:10.1136/bmj.g3769

329. Liang SH, Yang YH, Kuo TY, et al. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study. *Res Dev Disabil*. 2018;72:96-105. doi:10.1016/j.ridd.2017.10.023

330. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. *Drug Saf*. 2009;32(11):1089-1096. doi:10.2165/11317630-000000000-00000

331. Stuckelman ZD, Mulqueen JM, Ferracioli-Oda E, et al. Risk of irritability with psychostimulant treatment in children with ADHD: a meta-analysis. *J Clin Psychiatry*. 2017;78(6):e648-e655. doi:10.4088/JCP.15r1060

332. Pozzi M, Carnovale C, Peeters GGAM, et al. Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: a meta-analysis. *J Affect Disord*. 2017;238:161-178. doi:10.1016/j.jad.2018.05.021

333. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit/hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. *Drug Saf*. 2009;32(11):1089-1096. doi:10.2165/11317630-000000000-00000

334. Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. *Eur Child Adolesc Psychiatry*. 2017;26(11):1283-1307. doi:10.1007/s00787-017-0986-y

335. Bastiaens L. Improvement in global psychopathology increases quality of life during treatment of ADHD with atomoxetine or stimulants. *Psychiatr Q*. 2011;82(4):303-308. doi:10.1007/s11126-011-9172-4

336. Coghill D. The impact of medications on quality of life in attention-deficit/hyperactivity disorder: a systematic review. *CNS Drugs*. 2010;24(10):843-866. doi:10.2165/11537450-000000000-00000

337. Goetz M, Yeh CB, Ondrejka I, et al. A 12-month prospective, observational study of treatment regimen and quality of life associated with ADHD in central and eastern Europe and eastern Asia. *J Atten Disord*. 2012;16(1):44-59. doi:10.1177/1087054710381480

338. Benner-Davis S, Heaton PC. Attention deficit and hyperactivity disorder: controversies of diagnosis and safety of pharmacological and nonpharmacological treatment. *Curr Drug Saf*. 2007;2(1):33-42. doi:10.2174/15748867979315444

339. Ching C, Eslick GD, Poulton AS. Evaluation of methylphenidate safety and maximum-dose titration rationale in attention-deficit/hyperactivity disorder: a meta-analysis. *JAMA Pediatr*. 2019;173(7):630-639. doi:10.1001/jamapediatrics.2019.0905

340. Clavena A, Bonati M. Safety of medicines used for ADHD in children: a review of published prospective clinical trials. *Arch Dis Child*. 2014;99(9):866-872. doi:10.1136/archdischild-2013-304170

341. Didoni A, Sequi M, Panei P, Bonati M, Lombardy ADHD Registry Group. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder. *Eur J Clin Pharmacol*. 2011;67(10):1061-1067. doi:10.1007/s00228-011-1050-3

342. Holmskov M, Storebø OJ, Moreira-Maia CR, et al. Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. *PLoS One*. 2017;12(6):e0178187. doi:10.1371/journal.pone.0178187

343. Konrad-Bindl DS, Gresser U, Richartz BM. Changes in behavior as side effects in methylphenidate treatment: review of the literature. *Neuropsychiatr Dis Treat*. 2016;12:2635-2647. doi:10.2147/NDT.S14185

344. Safer DJ. Age-grouped differences in adverse drug events from psychotropic medication. *J Child Adolesc Psychopharmacol*. 2011;21(4):299-309. doi:10.1089/cap.2010.0152

345. Ghanizadeh A, Freeman RD, Berk M. Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials. *Rev Recent Clin Trials*. 2013;8(1):2-8. doi:10.2174/1574887111308010002

346. Storebø OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. *Cochrane Database Syst Rev*. 2018;5(5):CD012069. doi:10.1002/14651858.CD012069.pub2

347. Frank E, Ozon C, Nair V, Othee K. Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. *J Clin Psychiatry*. 2015;76(11):e1459-e1468. doi:10.4088/JCP.14r09478
348. Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder—a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543-1569. doi:10.2147/NDT.S65721

349. Arnold LE, Hodgkins P, Caci H, Kahle J, Young S. Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS One. 2015;10(2):e0116407. doi:10.1371/journal.pone.0116407

350. Boland H, DiSalvo M, Fried R, et al. A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res. 2020;123:21-30. doi:10.1016/j.jpsychires.2020.01.006

351. Chang Z, Ghirardi L, Quinn PD, Asherson P, D’Onofrio BM, Larsson H. Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry. 2019;86(5):335-343. doi:10.1016/j.biopsych.2019.04.009

352. Schachar R, Jadad AR, Gauld M, et al. Attention-deficit hyperactivity disorder: critical appraisal of extended treatment studies. Can J Psychiatry. 2002;47(4):337-348. doi:10.1177/070674370204700404

353. Ercan ES, Kose S, Kutlu A, Akyol O, Durak S, Aydin C. Treatment duration is associated with functioning and prognosis in children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bulteni. 2012;22(2):148-160. doi:10.5455/bcp.20120412021635

354. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113(4):762-769. doi:10.1542/peds.113.4.762

355. Molina BSG, Hinshaw SP, Swanson JM, et al; MTA Cooperative Group. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484-500. doi:10.1097/CHI.0b013e3181f9e23d0

356. Smith G, Jongeling B, Hartmann P, Russell C, Landau L. Raine ADHD Study: Long-term Outcomes Associated With Stimulant Medication in the Treatment of ADHD in Children. Western Australian Department of Health; 2010.

357. Elshaug AG, Rosenthal MB, Lavis JN, et al. Levers for addressing medical underuse and overuse: achieving high-value health care. Lancet. 2017;390(10109):191-202. doi:10.1016/S0140-6736(16)32586-7

360. Baker J. Schools must prepare for 50 percent rise in students with disabilities: report. The Sydney Morning Herald. February 9, 2020. Accessed March 5, 2021. https://www.smh.com.au/national/nsw/schools-must-prepare-for-50-per-cent-rise-in-students-with-disabilities-report-20200902-p55rrm.html

361. Hwang ES, Hyslop T, Lynch T, et al. The COMET (Comparison of Operative Versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9(3):e026797. doi:10.1136/bmjopen-2018-026797

SUPPLEMENT 1.
eAppendix 1. MEDLINE Search Strategy
eAppendix 2. Data Extraction Template
eAppendix 3. Flow Diagram of Included Studies
eAppendix 4. Qualitative Data Extraction
eAppendix 5. Critical Appraisal Results
eAppendix 6. Results Table
eReferences

SUPPLEMENT 2.
Data Extraction Results